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Aims and topics of research 
Matrix metalloproteinases (MMPs) are zinc dependent endopeptidases capable of 
degrading all kinds of extracellular matrix (ECM) proteins under normal physiological 
conditions. As MMPs have long been associated with many pathological conditions and 
in many stages of cancer, this protease family is a potential pharmaceutical target. Many 
inhibitors have been developed to therapeutically block the ECM degrading activities of 
MMPs in metastasis and angiogenesis. 
 
The recent approach to drug design is to understand the molecular determinants of 
specificity and selectivity. The structural information of the catalytic mechanism of 
MMPs is of great importance, as this information may provide a better insight of the 
entities involved in the interaction/inhibition and useful in designing new effective drug 
targets for this class of proteases.  
 
Aiming to address the question, the present research has been carried out to understand 
the molecular mechanism of catalysis of MMPs using MMP12 (or macrophage elastase) 
as a model, because of the high level of structural and functional homology within 
members of family. This project was focused on investigating the mechanism, at the 
molecular level, not only within the active site but also to its downstream or upstream 
sites and to design new candidate drugs with increased selectivity and specificity based 
on such structural and molecular information. In this context Full-length MMP12 and its 
catalytic and hemopexin-like domains were cloned and expressed in a high throughput 
fashion and structurally characterized utilizing various biochemical and biophysical 
techniques. 
 
One of the major problems to work with MMPs is their instability because of their high 
activity and auto-proteolysis property. A major part of the work was to standardize 
strategies and protocols to obtain pure protein with higher stability at the given conditions 
for longer duration required for NMR or other biophysical characterization. In this 
context, different mutants for catalytic domain and full-length have been cloned and 
successfully expressed in E.coli. Further, during the course of the work the protocol has 
been standardized to replace the catalytic zinc metal ion with an equivalent metal ion like 
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cadmium(II) or the paramagnetic metal ion cobalt(II) without affecting the structural 
conformation but with higher stability. 
Structurally, MMPs are multi-domains proteins. The flexibility of various domains in the 
protein and their ability to rearrange in the presence of the substrate represent a serious 
challenge against specificity. To accommodate the substrate in the active site, there is a 
necessity of relative mobility of the domains in the protein. In the attempt to understand 
the catalytic mechanism, a part of project has been devoted to address the hypothesized 
reorientation of the catalytic and hemopexin-like domains. The three dimensional 
structure of full-length MMP12 was solved by X-ray; the structure of the hemopexin-like 
domain was solved by NMR, while the structure of the catalytic domain was available 
both from X-ray and NMR. In particular the behavior of the catalytic and hemopexin-like 
domains in solution has been investigated to reveal the reciprocal mobility of these 
domains of MMP12. This finding might be relevant for other members of family having a 
shorter linker region between the two domains.  
 
The other fascinating area of research to understand the catalysis process is to investigate 
the substrate-enzyme recognition mechanism. In MMPs the catalytic domain alone bears 
full proteolytic activity towards a range of substrates. It is often hypothesized that the 
hemopexin-like domain helps in substrate/ligand recognition and binding and results in 
efficient proteolysis. However, for MMP12 it has been reported that the catalytic domain 
alone is able to degrade elastin without the hemopexin-like domain. To understand how 
such group of noncollagenase MMPs recognize and bind the substrate and elicit 
proteolysis is of particular importance in determining their physiological roles. In this 
context, the analysis of interaction of MMP12 with elastin can provide relevant 
information and might be fruitful to address the long debated role of hemopexin-like 
domain for this protease. Aiming to address this question, the project has recently 
developed in the direction of studying the interaction of individual domains as well as of 
full-length MMP12 with elastin and its components. Further, an attempt has been made to 
clone and express tropoelastin, the building block of elastin, in order to verify the 
molecular determinants of substrate recognition. 
 
In silico prediction of the structure of protein-ligand adducts through docking programs 
can provide valuable information in the early ligand design phases but cannot be used to 
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analyze the subtleties of interactions. By interpreting detailed structural information with 
a thermodynamic analysis of the ligand binding it is possible to clarify the driving force 
responsible for the affinity. In this way it is possible to plan modifications of the ligand 
able to increase its affinity and selectivity. In this respect we have solved the crystal 
structure of MMP12 in complex with a selective inhibitor and characterized the 
interaction in solution by NMR and microcalorimetry. 
 
Another fascinating aspect of drug design is the design of molecular probes able to 
selectively bind biomolecular targets. This approach is gaining importance not only for 
its many possible applications in molecular biology, but also for the development of new 
techniques for the early stage diagnosis and therapy of several pathologies. MMPs 
expression and activation is increased in almost all human cancers comparing to 
physiological conditions. It is therefore apparent that the development of efficient 
molecular devices designed to reveal the overexpression of MMP may be a powerful tool 
for the early detection of tumors. In this aspect, utilizing the extensive structural and 
biochemical information that we have gained on MMP12, a part of the present work 
involved the design and synthesis of carboxylic-based biotinylated inhibitors able to 
show high affinity for several MMPs and at the same time able to strongly interact with 
avidin through the biotinylated tag.  
 
The present thesis is based on the following articles: 
 
 Bertini, I., Calderone, V., Fragai, M., Jaiswal, R., Luchinat, C., Melikian, M., 
Mylonas, E., Svergun, D. I. (2008) Evidence of reciprocal reorientation of the 
catalytic and hemopexin-like domains of full length MMP-12. J Am Chem Soc, 
130 (22), 7011-21, 
 
 Calderone, V., Dragoni, E., Fragai, M, Jaiswal, R., Luchinat, C., Nativi, C. 
Biotin-Tagged Probes for Profiling of MMPs Expression and Activation: 
Design, Synthesis and Binding Properties (Submitted to Bioconjug. Chem.), 
 
 Structural and Thermodynamic analysis of a selective inhibitor of Matrix 
Metalloelastase (In preparation). 
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2.1 Extracellular Matrix (ECM) 
In biology, the extracellular matrix (ECM) is the extracellular part of animal tissues 
that usually provides structural support to the cells in addition to performing various 
other important functions. The extracellular matrix is the defining feature of 
connective tissue in animals. Extracellular matrix includes the interstitial matrix and 
the basement membrane (1). Interstitial matrix is present between various cells (i.e., in 
the intercellular spaces). Gels of polysaccharides and fibrous proteins fill the 
interstitial space and act as a compression buffer against the stress placed on the ECM 
(2) (Fig. 1). Basement membranes are sheet-like depositions of ECM on which various 
epithelial cells rest. 
 
 
 
Role and Importance: 
Due to its diverse nature and composition, the ECM can serve many functions, such as 
providing support and anchorage for cells, segregating tissues from one another, and 
regulating intercellular communication. The ECM regulates a cell's dynamic behavior. 
In addition, it sequesters a wide range of cellular growth factors, and acts as a local 
depot for them. Changes in physiological conditions can trigger protease activities that 
cause local release of such depots. This allows the rapid and local growth factor-
mediated activation of cellular functions, without de novo synthesis. 
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An understanding of ECM structure and composition also helps in comprehending the 
complex dynamics of tumor invasion and metastasis in cancer biology as metastasis 
often involves the destruction of extracellular matrix (3). 
 
Molecular components 
Components of the ECM are produced intracellularly by resident cells, and secreted 
into the ECM via exocytosis (4). Once secreted then they aggregate with the existing 
matrix. The ECM is composed of: 
 
Proteoglycan matrix components 
Glycosaminoglycans are carbohydrate polymers and are usually attached to 
extracellular matrix proteins to form proteoglycans. Proteoglycans have a net negative 
charge that attracts water molecules, keeping the ECM and resident cells hydrated.  
Heparan sulfate proteoglycans, Chondroitin sulfate proteoglycans, Keratan sulfate 
proteoglycans are various types of proteoglycans. 
 
Non-proteoglycan matrix components 
Hyaluronic acid, Collagen, Fibronectin, Elastin and Laminin 
 
Cell adhesion to the ECM 
Many cells bind to components of the extracellular matrix. This cell-to-ECM adhesion 
is regulated by specific cell surface cellular adhesion molecules (CAM) known as 
integrins. Integrins are cell surface proteins that bind cells to ECM structures, such as 
fibronectin and laminin, and also to integrin proteins on the surface of other cells. 
 
Cell types involved in ECM formation 
There are many cell types that contribute to the development of the various types of 
extracellular matrix found in plethora of tissue types. The local components of ECM 
determine the properties of the connective tissue. 
Fibroblasts are the most common cell type in connective tissue ECM, in which they 
synthesize, maintain and provide a structural framework; fibroblasts secrete the 
precursor components of the ECM, including the ground substance. Chondrocytes are 
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found in cartilage and produce the cartilagenous matrix. Osteoblasts are responsible 
for bone formation. 
 
2.2 Matrix Metalloproteinases (MMPs) 
Matrix Metalloproteinases, abbreviated as MMPs are family of zinc dependent 
endopeptidases that in normal physiological conditions are responsible for the 
regulation of extracellular matrix. MMPs were initially discovered in 1962 as Gross 
and Lapiere reported that tadpole tails during metamorphosis contained an enzyme 
that could degrade fibrillar collagen (5). They are included in the “MB clan” of 
metallopeptidases, containing the motif HEXXHXXGXXH as the zinc-binding active 
site. The MB clan members are generically referred to as “Metzincins” since they all 
contain a conserved methionine that forms a turn eight residues downstream from the 
active site. Clan MB contains a number of families, and MMPs are in family M10. 
Family M10 is further divided into subfamilies A and B, and MMPs are in subfamily 
A, also known as the “matrixins.” MMPs from vertebrate species are given MMP 
numbers (i.e. MMP1, MMP2, etc.), and MMPs from invertebrates rely on trivial 
names. The MMP family consists of at least 26 members, all of which share a 
common catalytic core with a zinc molecule in the active site.  
 
The MMPs are produced as zymogens, with a signal sequence and propeptide segment 
that must be removed during activation. The propeptide domain contains a conserved 
cysteine, which chelates the active zinc site. An exception is MMP-23 which lacks this 
conserved cysteine, and has a very different propeptide domain. The generally 
conserved sequence PRCGVP around the chelating cysteine has been called the 
“cysteine switch.” A subset of MMPs, including the membrane bound MMPs (MT-
MMPs), as well as MMP- 11, MMP-21, MMP-23, and MMP-28, contain a basic 
prohormone convertase cleavage sequence (RRKR, RRRR, RKRR, etc.), which is 
thought to be cleaved by the PACE/Furin family enzymes. Two of the MMPs (MMP-2 
and MMP-9) contain a fibronectin-like domain inserted into the catalytic domain, 
presumably to enhance substrate binding. MMP-9 also contains a collagen type-V-like 
domain, which may enhance substrate binding and specificity. MMP-21 from 
Xenopus also contains a vitronectin-like region just after the cysteine switch, 
presumably to assist in substrate interaction. 
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Though, initially classified as proteinases capable of digesting structural components 
of ECM, MMPs proteolytic targets expanded to several other extracellular matrix 
proteins. This wide range of substrates includes many other proteases, protease 
inhibitors, clotting factors, chemotactic molecules, latent growth factors, growth factor 
binding proteins, cell surface receptors, and cell-cell and cell matrix adhesion 
molecules (6). Functional regulation of MMPs occurs at multiple levels. MMP mRNA 
expression is under tight, cell type– dependent control, with expression of individual 
MMPs associated with specific inflammatory, connective tissue, or epithelial cell 
types. MMP transcripts are generally expressed at low levels, but these levels rise 
rapidly when tissues undergo remodeling, such as in inflammation, wound healing, 
and cancer. MMPs can be categorized into various subgroup depending on the 
structure or function basis. 
 
2.3 Structural and Functional Classification of MMPs 
Earlier, MMPs were divided into subgroup on the basis of their specificity for the 
ECM components and thus reflects in the common name e.g., Collagenases, 
Gelatinases, Stromelysins and matrilysins (Fig.2). 
 
 
All MMPs have an N-terminal signal sequence (or “pre” domain) that is removed after 
it directs their synthesis to the endoplasmic reticulum. Thus most MMPs are secreted; 
however, six display transmembrane domains and are expressed as cell surface 
enzymes. The pre domain is followed by a propeptide “pro” domain that maintains 
17
 
enzyme latency until it is removed or disrupted, and a catalytic domain that contains 
the conserved zinc-binding region (7). The catalytic domain dictates cleavage site 
specificity through its active site cleft, through specificity sub-site pockets that bind 
amino acid residues immediately adjacent to the scissile peptide bond, and through 
secondary substrate-binding exosites located outside the active site itself (8). With the 
exception of MMP7 (matrilysin), MMP26 (endometase/matrilysin-2), and MMP23, all 
MMPs have a hemopexin/vitronectin-like domain that is connected to the catalytic 
domain by a hinge or linker region. MMP7 and MMP26 merely lack these extra 
domains, whereas MMP23 has unique cysteine-rich, proline-rich, and IL-1 type II 
receptor-like domains instead of a hemopexin domain (9, 10).  
With the increasing range of substrates, MMPs are now sequentially numbered and 
grouped according to their structures. On the structural basis MMPs are categorized in 
8 classes, five of which are secreted and three are membrane-type (MT) MMPs 
(Fig.3). 
 
 
2.4 MMPs: Normal physiological regulation and Diseases 
The pericellular MMPs are believed to be the physiological mediators of matrix 
degradation or turnover and, collectively, the MMPs can cleave all protein 
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components of the extracellular matrix (ECM) (11). Indeed, many peptides liberated by 
the partial proteolysis of ECM macromolecules can regulate cell activities. Besides the 
ECM, other substrates of MMP processing include growth factors, receptors and 
adhesion molecules (12).  
These activities confer on MMPs functions as diverse as cellular differentiation, 
migration, regulation of growth factor activity, survival or apoptosis, angiogenesis, 
inflammation and signaling (13, 14). The normal possible modes of action of MMPs are 
depicted in Fig.4. The simplicity of thinking about MMPs solely as extracellular 
matrix degrading enzymes has been eroded by the recognition of numerous other 
important roles for these proteins.  
 
 
 
Participation of the MMPs in various aspects of Cancer 
MMPs are collectively able to degrade virtually all ECM components. In cancer, 
special emphasis was initially placed on the degradation of type IV collagen, a major 
protein component of basement membranes by MMP2 and MMP9. Subsequently, it 
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has been demonstrated that many non-ECM proteins can be cleaved by selected 
MMPs. Deciding which protein substrates are physiologically and pathologically 
relevant has been difficult to ascertain.  
 
MMP-induced release from the cell surface (shedding) of heparin binding epithelial 
growth factor, insulin-like growth factor, and fibroblast growth factor enhance cell 
proliferation. On the other hand, release and activation of ECM sequestered TGFß by 
MMPs can lead to inhibition of cell proliferation. MMPs are capable of inducing both 
positive and negative effects on angiogenesis and immunity (Fig. 5). It has been 
observed that some MMPs readily cleave specific chemokines which may have 
profound effects on numerous biologic processes, not just limited to inflammation (15, 
16). 
Most MMPs in tumors are produced by stromal cells rather than the cancer cells (Fig. 
6). One explanation for this phenomenon is that cancer cells produce Extracellular 
Matrix Metalloproteinase Inducer (EMMPRIN), a cell surface glycoprotein, which 
directly stimulates fibroblasts (through direct cell contact) to produce set of MMPs (17). 
The importance of cytokines such as TNF-α, interleukin (IL)-1, and IL-6 in 
stimulating production of MMPs in disease has been emphasized.  
 
20
  
Inflammatory diseases  
Many reports have implicated MMP1, MMP3, and MMP9 in rheumatoid and 
osteoarthritis. An important role for aggrecanase, a member of the ADAM family of 
metalloproteinases, in articular damage has been proposed. A clinical trial of an 
MMPI in arthritis failed to achieve its goal. 
 
Cardiovascular disease 
There has been a long-standing interest in the role of MMPs in cardiovascular disease. 
Numerous studies have demonstrated increased levels of MMPs at sites of 
atherosclerosis and aneurysm formation (18). The concept that the inflammatory 
process may play a leading role in the development of atherosclerotic plaques, has led 
to the suggestion that secretion and activation of MMPs by macrophages induces 
degradation of extracellular matrix in the atherosclerotic plaque and plaque rupture.  
 
Lung disease 
Elevated levels of MMPs have been implicated in the pathophysiology of various lung 
diseases, including acute respiratory distress syndrome, asthma, bronchiectasis, and 
cystic fibrosis. MMPs, EMMPRIN, and TIMPs are produced by many of the resident 
cells in the lung, hence complicating the analysis of their role in disease.  
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Central Nervous System disease 
Following observations of the critical role of MMP9 in animal models resembling 
multiple sclerosis and Guillain-Barre’s syndrome, MMPs has been implicated in 
several different types of neurologic diseases (19). Treatment with synthetic inhibitors 
of MMPs has reversed some of the pathology in animal models of brain injury, 
especially stroke.  
 
Shock syndromes 
MMP8 and MMP9 are stored in the granules of polymorphonuclear leukocytes. These 
cells are key effectors in inflammatory and infectious processes. A role for these 
MMPs in shock is supported by studies in MMP9 deficient mice that were shown to 
be resistant to endotoxic shock (20). 
 
Chronic wounds and inflammation of the skin and oral cavity 
Acute and chronic wounds are associated with high levels of MMP2 and MMP9. 
These observations have led to the suggestion that nonhealing ulcers develop an 
environment containing high levels of activated MMPs, which results in chronic tissue 
turnover and failure of wound closure. MMP9 has been implicated in blistering skin 
diseases and contact hypersensitivity (21). MMPs have long been implicated in 
periodontal disease (22) and more recently, in inflammatory bowel diseases.  
 
2.5 Matrix Metalloproteinase 12 or Metalloelastase 
MMP12 also known as Macrophage Elastase or Metalloelastase is a member of matrix 
metalloproteinase (MMP) gene family was first detected by Werb and Gordon in 1975 
when they identified the elastolytic activity in mouse peritoneal macrophage conditioned 
media (23). Like other members of MMPs family, MMP12 shares many features typical of 
MMPs including the domain structure, chromosomal location in MMP gene cluster in 
human chromosome 11q22, and to degrade components of ECM (24). As other MMPs, 
MMP-12 is composed of three distinct domains: an amino-terminal propeptide domain 
that is involved in the maintenance of enzyme latency; a catalytic domain that binds zinc 
and calcium ion and hemopexin-like domain at the carboxy terminal which determines 
substrate specificity. The human gene, which is designated human macrophage 
metalloelastase, produces a 1.8-kb transcript encoding a 470-amino acid protein (Fig. 7) 
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that is 64% identical to the mouse protein. MMP-12 is secreted as a 54-kd pro-form 
protein that undergoes self-activation through autolytic processing (25). Both the mRNA 
and protein were detected in alveolar macrophages.  
 
 
 
MMP-12 is unique with respect to its predominantly macrophage-specific pattern of 
expression and the ability to readily shed its carboxyl-terminal domain upon processing. 
It degrades a broad range of ECM proteins, including elastin, type IV collagen, 
fibronectin, laminin and gelatin (26), and is involved in turnover of the matrix, cell 
migration, tissue repairing and remodeling. In addition, MMP-12 can activate other 
MMPs, for example, MMP-2 and -3, leading to subsequent degradation of other ECM 
proteins (27). MMP-12, like other MMPs, also cleaves a variety of non-ECM proteins, 
such as plasminogen (28) and latent tumor necrosis factor α (TNFα), resulting in 
angiostatin and active TNFα, (29) respectively. Because of its great ability to degrade 
ECM, it is physiologically synthesized and released by macrophages to penetrate 
basement membranes and to invade normal and diseased tissue. The extensive role of 
Metalloelastase both in physiological and pathological conditions makes the enzyme an 
important target for medical research.  
 
2.6 MMP12 in diseases 
MMP12 was first detected in alveolar macrophages of cigarette smokers, but since then 
MMP-12 production has also been shown in other cell types and organs, e.g. in brain 
tumors (30) and placenta (31). Elastin serves an important function in arteries and is 
particularly abundant in large elastic blood vessels such as the aorta. Elastin is also very 
important in the lungs, elastic ligaments, the skin, the bladder, elastic cartilage, and the 
intervertebral disc above the sacroiliac. Abnormal expression of MMP12 in these tissues 
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thus results in various pathological conditions in particular to those associated with the 
respiratory tract (32). 
 
Emphysema 
Chronic obstructive pulmonary disease (COPD) is a major global healthcare problem 
with tremendous morbidity and high mortality rates. Emphysema is defined as 
enlargement of peripheral airspaces of the lung accompanied by destruction of the walls 
of these structures (33). The pathological hallmarks of the disease are small airway 
inflammation and obstruction and destruction of the ECM of the lung parenchyma that 
eventually lead to emphysema (34). Chronic cigarette smoke (CS) exposure, which is 
associated with chronic inflammation and oxidative stress within lungs (35), is regarded as 
the primary cause of emphysema (36). It is characterized by an accumulation of 
inflammatory cells such as macrophages and neutrophils. Indeed, it has been shown that 
cigarette smoke consistently produces an increase in the neutrophil number in 
bronchoalveaolar lavage fluid and in tissue (37, 38, 39). Macrophage numbers are also 
elevated in the lungs of smokers and patients with COPD where they accumulate in the 
alveoli, bronchioli and small airways. Furthermore, there is a positive correlation between 
macrophage number in the alveolar walls and the mild-to-moderate emphysema status in 
patients with COPD (40). Studies in mice demonstrated that macrophage-mediated lung 
alveoli destruction (emphysema) following cigarette smoke exposure is directly linked to 
the presence of MMP-12 (41) (Fig. 8). Thus, macrophage elastase is required for both 
macrophage accumulation and emphysema resulting from chronic inhalation of cigarette 
smoke. 
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Vascular Aneurysms 
Abdominal aortic aneurysms (AAA) affect between 2% and 9% of adults older than 65 
years of age. AAAs is associated with aging, atherosclerosis, cigarette smoking, and male 
gender. AAAs is believed to result from structural remodeling of the elastin-rich aortic 
wall in association with chronic transmural inflammation. Mononuclear cell infiltration in 
the aortic media associated with elastic fiber destruction might be of particular 
importance. MMP-9 (42) and MMP-12 (43) were found to be prominently expressed in 
macrophages associated with elastic fiber disruption in specimens of human abdominal 
aortic aneurysm. Production of macrophage elastase was increased seven-fold in patients 
with aneurysms, and unlike other proteinases, expression was localized to the active 
“transition zone” in the media. This is the region adjacent to normal aorta where there is 
active remodeling and elastin degradation. Unlike other MMPs, macrophage elastase also 
specifically bound to fragmented, but not intact, elastic fibers in this zone. In vitro studies 
confirmed that macrophage elastase has a greater binding affinity for elastin than other 
elastases. These findings suggest that macrophage elastase might play a central role in 
aneurysm formation in humans. 
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Cancer 
MMPs are believed to promote tumor progression by initiating carcinogenesis, enhancing 
tumor angiogenesis, disrupting local tissue architecture to allow tumor growth, and 
breaking down basement membrane barriers for metastatic spread. Several serine (44, 45) 
and metalloproteinases are capable of generating angiostatin (46) and other antiangiogenic 
plasminogen cleavage products, such as kringle domain 5 (47). Generation of angiostatin 
in primary LLC tumors correlated with the presence of macrophages and macrophage 
elastase (48, 49). With respect to MMPs, MMP-12 has the greatest proteolytic capacity to 
generate angiostatin from plasminogen. In fact, in the presence of plasminogen, wild-type 
murine macrophage conditioned medium acquires the capacity to inhibit endothelial cell 
proliferation by more than 50%. This effect is not observed in MMP-12-deficient 
macrophages. The importance of MMP-12 in limiting lung metastasis growth in the LLC 
model has been confirmed by use of mice deficient in macrophage elastase (MMP-12-/-) 
by gene-targeting. Studies suggest that local expression of MMP-12 in macrophages 
surrounding lung metastases limit growth. This effect does not appear to be related to 
generation of angiostatin. MMP12 is also expressed in malignant cells such as skin 
cancer, (50) astrocytomas, glioblastomas, (51) and hepatocellular cancer, in which its 
expression is associated with hypovascularization (52, 53). This might be caused by the 
ability of MMP12 to cleave plasminogen to angiostatin and other kringle products, 
leading to the inhibition of angiogenesis in these tumors. (54, 55). 
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3. Methodological Aspects 
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3.1 Structural Genomics/Proteomics approach 
The essence of structural genomics is to start from the gene sequence, produce the protein 
and determine its three-dimensional structure. The challenge, once the structure is 
determined, is to extract useful biological information about the biochemical and 
biological role of the protein in the organism. This is a complete reversal of the classical 
structural biology paradigm, where a protein structure is determined to understand how it 
performs its known biological function at the molecular level and its implications for 
drug design and target discovery. It is first useful to summarize what information can and 
cannot be derived from structural data (Fig. 9). The structure reveals the overall 
organization of the protein chain in three dimensions. From this we can identify the 
residues that are buried in the core or exposed to solvent on the protein surface, the shape 
and molecular composition of the surface, and the relative juxtaposition of individual 
groups. It also reveals the quaternary structure of the protein in the crystal environment or 
in solution at high concentration. Protein–ligand complexes are perhaps the most useful 
for functional information, since they reveal the nature of the ligand, where it is bound in 
the protein and, if the protein is an enzyme, the disposition of residues in the active site, 
from which a catalytic mechanism may be postulated. Before considering how to extract 
functional information, it is important to emphasize that structural data usually only carry 
information about the biochemical function of the protein. Its biological role in the cell or 
organism is much more complex and additional experimental information is needed in 
order to elucidate this. How then can structural information are used to infer functional 
knowledge? Comparison of the protein fold (1) or structural motifs within a protein to the 
structural databases may reveal similarities, from which biochemical and biological 
functional information may be inferred (2). This knowledge-based approach is by far the 
most powerful method for predicting function from structure. All new structures are now 
scanned against the databases of known structures to find such relatives. The impact of 
structural genomics on target discovery and rational drug design is not clear. For target 
discovery, the hope is that the structures will reveal functions of proteins of relevance for 
therapy, thus providing new targets. The structures will also be valuable in deciding 
whether the protein is a suitable target for small molecule inhibitors (that is, ‘drugable’), 
through analysis of its binding site character. 
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Knowledge of the distribution of proteins between species will be important auxiliary 
information to identify species-specific targets and to try to avoid toxicity problems. The 
structures may also prove useful in understanding and ultimately predicting cross-
reactions of a small molecule with non-targeted proteins in the same organism, which can 
lead to multiple side effects. This will help to prioritize candidate targets, streamline the 
drug development pipeline, and hopefully reduce the number of failures downstream. For 
structure-based drug design, most chemists would argue that they need very high-
resolution structures, preferably with multiple ligands. Here, although the high-
throughput methods developed in the structural genomics projects will facilitate rapid 
structure determination, the need for high-resolution data is unlikely to change. However 
as more structures become available, it will gradually become the ‘norm’ for the 
development process for a new drug to incorporate knowledge of its target structure. 
Even today many of the newest drugs have been designed using a combination of 
combinatorial chemistry and intelligent structure-based design to bias libraries or to 
refine the lead molecule. Successful structure-based drug design in silico is still a goal to 
work toward, but as more structural data become available we can expect theoretical 
approaches to improve considerably. 
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3.2 Domain definition 
As discussed above MMPs are structurally multi domains proteases composed minimally 
of an N-terminal signal sequence followed by the prodomain, catalytic domain and a C-
terminal Hemopexin-like domain as in their simplest structure. In the current work 
various domains of MMP12 were cloned and expressed. There are various preliminary 
analyses needed in order to the best construct in terms of yield, solubility and 
purification.  
Different constructs for MMP12 Catalytic (Cat) domain (Wild type and mutants), 
Hemopexin-like (Hpx) domain and Catalytic-Hemopexin-like (CatHpx) domain (Wild 
type and mutants) were cloned during the course of work. The different domains of the 
protein were defined and characterized by the use of available domain architectural 
bioinformatics tools such as Simple Modular Architectural Research Tool (SMART) (3) 
(http://smart.embl-heidelberg.de/) and/or Pfam (http://pfam.sanger.ac.uk/). On the basis 
of the results from the domain architectural tools, various constructs for domains were 
cloned and standardized for the expression in the prokaryotic host system (Escherichia 
coli, as in the current work). 
 
3.3 Gene Cloning 
Structural genomics consists in the determination of the three dimensional structure of all 
proteins of a given organism, by experimental methods such as X-ray crystallography, 
NMR spectroscopy or computational approaches such as homology modeling (4). This 
raises new challenges in structural bioinformatics, i.e. determining protein function from 
its 3D structure. Structural genomics emphasizes high throughput determination of 
protein structures. Thus, the need of high throughput protein preparation is one of the 
challenging and emerging aspects of structural genomics or structural proteomics (5). The 
ever fasting developments of techniques for cloning, expression, purification of proteins 
are thus the backbone of structural genomics or proteomics project. Molecular cloning 
refers to the procedure of isolating a defined DNA sequence and obtaining multiple 
copies of it in vivo. Cloning is frequently employed to amplify DNA fragments 
containing genes, but it can be used to amplify any DNA sequence (6). 
 
The strategy used in gene cloning involves: 
? the gene of interest is amplified by PCR. 
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? the PCR product is cloned into a specific cloning/expression vector and amplified. 
? the sequence of a positive clone is checked by sequence analysis. 
? the positive clone is transformed into a variety of expression systems. 
 
Cloning can be done by any of the method: 
1. Classical method using restriction enzyme 
2. TA Cloning and TOPO TA Cloning 
3. Recombination Cloning systems 
? Gateway Cloning Technology (Invitrogen) 
? Creator (BD Clontech) 
 
In the present work, the classical cloning method (Fig. 10), which involves the use of 
restriction enzymes, has been used for cloning of different constructs of MMP12. 
Restriction enzymes (restriction endonucleases) are molecular scissors that cuts DNA at 
(or close to) specific recognition sites (7). Two types of restriction enzymes exist that 
differ in the way they cut the target DNA: 
? Blunt end cutters. These enzymes cut both strand of the target DNA at the same 
spot creating blunt ends. 
? Sticky end cutters. These enzymes cut both strand of the target DNA at different 
spots creating 3'- or 5'-overhangs of 1 to 4 nucleotides (so-called sticky ends). 
 
To be able to clone a DNA insert into a cloning or expression vector, both insert and 
vector have to be treated with two restriction enzymes that create compatible ends (8, 9). 
The next step is the ligation of the insert into the linearized vector. This involves the 
formation of phosphodiester bonds between adjacent 5'-phosphate and 3'-hydroxyl 
residues, which can be catalyzed by ligase: 
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In the present work different domains of MMP12 (Cat, Hpx, and Cat-Hpx) were cloned 
using the above mentioned cloning strategy. NdeI and XhoI restriction enzymes (New 
England Biolabs) were used for all the constructs in pET21a vector (Novagen) using T4 
DNA Ligase for ligation. All the constructs (Fig. 11) designed for the protein to be 
expressed as native means without any kind of fusion tag to enhance the solubility or ease 
of purification.  
 
 
The cloning vector with the inserted gene then transformed and amplified in E.coli DH5α 
strain and the positive clones were selected by streaking the transformed cells on the 
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selective antibiotic media plate (Ampicillin in the present case). The antibiotic resistant 
colonies suppose to have the gene of interest incorporated within was confirmed by PCR 
screening and checked on 1.5% Agarose Gel and further by sequence analysis (at 
PRIMM Biotech SRL, MILAN). The positive clone after sequencing results were 
transformed in various expression systems available in the laboratory for protein 
expression. 
3.4 Site-directed mutation 
MMP12 and in general almost all MMPs in their active form are prone to the autolysis or 
self-digestion. This makes it an unsuitable protein to work with for a longer duration of 
time Mutation of residue at active site within the catalytic domain without disturbance in 
the structure conformation is the best solution to over come the autolysis problem. 
Bioinformatics studies and models generated using bioinformatics tools as well as from 
literature survey it is discovered that mutation of Glutamic Acid to Alanine at position 
219 (E219A) in the active site results in decreased activity to several magnitude though 
the structural conformation fully retained. Further bioinformatics studies shows that 
mutation of Phenylalanine to Aspartic Acid at position 171 (F171D), a site presented 
far upstream to the active site, results in better solubility of MMP12. The development of 
fast and easy site-directed mutagenesis technique helps in achieving the mutation. 
 
Site-directed mutagenesis, also known as site-specific or oligonucleotides-directed 
mutagenesis is the technique of molecular biology which is used to make mutation at a 
defined site in the DNA molecule (10). Discovered lately in 1970s, the method gained 
popularity in the recombinant DNA technology because of its numerous advantages over 
the classical random mutagenesis technique (11). The method is used to make point 
mutation, switch amino acid, insertion, duplication, deletion of single or multiple amino 
acids.  
 
The method implies the use of PCR with oligonucleotides "primers" that contain the 
desired mutation. As the primers are the ends of newly-synthesized strands, there should 
be a mismatch during the first cycle in binding the template DNA strand, after that first 
round, the primer-based strand (containing the mutation) would be at equal concentration 
to the original template. After successive cycles, it would exponentially grow, and after 
38
 
25, would outnumber the original, unmutated strand in the region of 8 millions to 1, 
resulting in a nearly homogeneous solution of mutated amplified fragments.  
 
Despite the fact that the PCR product is overwhelmingly composed of mutated plasmid, 
the template DNA is typically eliminated by enzymatic digestion with DpnI, a restriction 
enzyme which cleaves only Dam methylated DNA (12). The template, which is derived 
from an alkaline lysis plasmid preparation and therefore is methylated, is destroyed in 
this step, but the mutated plasmid is preserved because it was generated in vitro and is 
unmethylated as a result (Fig. 12).  
 
The mutagenic oligonucleotide primers must be designed individually to incorporate the 
desired point mutation or degenerate codon. The following considerations should be 
made when designing mutagenic primers: 
 
? All of the primers used for simultaneous mutagenesis must anneal to the same 
strand of the template plasmid. In most cases, primers binding to either strand will 
be incorporated into mutant plasmids with equal efficiency.  
? Primers may be designed to bind to adjacent sequences or to well separate regions 
on the same strand of the template plasmid.  
? Primers should be between 25 and 45 bases in length, with a melting temperature 
(Tm) of ≥75°C. Primers longer than 45 bases may be used, but using longer 
primers increases the likelihood of secondary structure formation, which may 
affect the efficiency of the mutagenesis reaction. Optimum primer sets for 
simultaneous mutagenesis should have similar melting temperatures.  
 
The following formula is commonly used for estimating the Tm of primers: 
Tm = 81.5 + 0.41(%GC) – 675/N – % mismatch 
• N is the primer length in bases 
• values for %GC and % mismatch are whole numbers 
During the course of work single mutant F171D, single mutant E219A, double mutant 
F171D, E219A for catalytic domain as well as single mutant F171D, single mutant 
E219A, double mutant F171D, E219A, double mutant F171D, N268D, triple mutant 
F171D, E219A, N268D for Cat-Hpx domains of MMP12 has been designed as per above 
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mentioned strategy by either point mutation or amino acid switch using Stratagene’s 
multi site-directed mutagenesis kit (Catalog #200514 and #200515). 
 
 
 
3.5 Protein Expression 
Protein overexpression the term given to the condition in which the protein encoded by a 
gene is expressed in a large amount. This can be achieved by increasing the copy number 
of the gene responsible for the production of particular protein or by increasing the 
binding strength of the promoter region (13). Bacteria are good expression system for the 
overexpression of human recombinant proteins which required in large amount for the 
biophysical characterization using NMR or X-ray Crystallography or in a broad term in 
structural genomics. Overexpression is the state where about 30% of the total protein 
population is the desired protein. 
 
Once the positive clone obtained, there are some preliminary analysis in order to 
standardize the expression conditions. The clones are transformed in a variety of 
expression host systems for comparisons of better expression. A small trial/test 
expression culture is usually perform in order to optimize the growth conditions which 
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includes agitation rate, temperature, inducer concentration, culture duration, etc. Protein 
from the small scale cultures is useful in optimizing the purification protocols. As the 
small scale culture got standardized the next step is to scale up the cultures using the 
refined conditions in shaker flask condition or in fermentors.  
 
Here are the conditions optimized for overexpression of different domains of MMP12 in 
bacterial expression systems during the course of work: 
 
MMP12 Catalytic domain (Gly106-Gly263): 
The Cat domain (Wild-type, F171D single mutant, E219A single mutant, F171D, E219A 
double mutant) found to have optimal expression in E.coli BL21 (DE3) expression 
system. The cells were grown in LB medium containing 50 μg/ml of Ampicillin in a 
shaker flask at 37° C with agitation rate 180 rpm. Protein expression was induced with 
0.5 mM IPTG at an OD600 = 0.6, and cell growth was continued for a further 5 h. For 13C 
and 15N labeled protein the amount of 13C-enriched Glucose and 15N-enriched 
Ammonium Chloride (Cambridge Isotopes Laboratories) were optimized to 2.5gm/l and 
1.2gm/l of minimal media.  
 
MMP12 Hemopexin-like domain (Glu278-Cys470): 
The expression vector encoding the Hpx domain was transformed in E.coli BL21 (DE3) 
cells. Bacterial cells were grown in LB medium containing 50 μg/ml of Ampicillin in a 
shaker flask at 37° C with agitation rate 180 rpm. Protein expression was induced with 
0.5 mM IPTG at an OD600 = 0.6, and cell growth was continued for overnight. Labeled 
culture in minimal media was done as metioned above for catalytic domain. 
 
MMP12 Cat-Hpx domain (Gly106-Cys470): 
Wild type Cat-Hpx as well as other 6 mutants for Cat-Hpx domain for optimal expression 
were transformed in E.coli BL21 (DE3) Codon Plus RIPL strain. The cells were grown at 
37° C, 180 rpm in shaker flasks in LB medium containing 34 μg/ml of Chloramphenicol 
and 50 μg/ml of Ampicillin. Induction of protein carried out with 0.5 mM IPTG at an 
OD600 = 0.6, and cell growth was continued for overnight. Labeled culture in minimal 
media was done as mentioned above for catalytic domain. 
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3.6 Protein Purification 
The strategy of purification depends mainly upon the location of the expressed protein 
within the host, indeed, the protein can be transported in the periplasmic space or 
expressed like a soluble or insoluble (inclusion bodies) protein within the cytoplasm (14). 
In each case, the isolation was performed in a different way. All the purification involve 
several is chromatographic steps performed adjusting the parameters according to the 
different physical chemical and biological characteristics of the proteins. Ion exchange 
(15) (Fig. 13) and size exclusion (16) chromatography (Fig. 14) are commonly used to 
purify proteins expressed in their native states. Some tags, like MBP or GST, are specific 
affinity tag, which not only facilitate soluble expression but also increase the efficiency 
of protein purification. In some cases, other solubility tags have been combined with a 
simple His-tag, allowing the fusion partner to maintain its solubilizing functionality and 
also simultaneously as affinity tag. 
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For all domains of MMP12, irrespective of various fusion tags, the proteins were 
expressed as insoluble form in inclusion bodies. Thus to extract the protein from the 
inclusion bodies, protein was denatured using strong denaturing agent such as 8M Urea 
or 6M Guandinium Chloride. This result in an unfolded protein which needs to be refolds 
to its original conformation. Hence, refolding protocols were optimized. Here described 
are the protein purification methods for individual domains: 
 
MMP12 Cat (Wild type and Mutants): 
Cells were harvested by centrifugation, resuspended in 25% Sucrose, 50mM Tris-HCl 
(pH 8), 0.1M NaCl, 0.2M EDTA, 1mM DTT. 5-10 mg Lysozyme was added to the 
resulting suspension and stirred for 15-20 min. at 4°C.  Buffer containing 2% Triton, 
50mM Tris-HCl (pH 8), 0.1M NaCl, 0.2M EDTA, 1mM DTT was added and sonicated 
(7-8 cycles of 30 seconds) and centrifuged at 40000 rpm for 20 minutes at 4°C. The 
pellets were washed with 50mM Tris, 5mM EDTA, 1mM DTT (pH 8) and centrifuged. 
The resulting inclusion bodies were solublized in 8M Urea, 20mM Sodium Acetate (pH 
5). The insoluble material was removed by centrifuging at 9000 rpm for 10 minutes. 
Protein molecular weight and purity was checked on 15% Gel by SDS-PAGE.  
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Protein was purified with Cation Exchange chromatography using HiTrap SP column 
using a gradient of NaCl up to 350mM (6M Urea, 20mM Sodium Acetate, pH 5). The 
purified protein was refolded by serial dilution method. The protein was diluted to a final 
concentration of 0.10mg/ml in 4M Urea, 20mM Tris-HCl, 10mM CaCl2, 0.1mM ZnCl2, 
0.3M NaCl (pH 7.2), dialysed overnight against same buffer (4M Urea, 20mM Tris-HCl, 
pH 7.2, 10mM CaCl2, 0.1mM ZnCl2, 0.3M NaCl) successively followed by two steps 
with Buffer B (2M Urea, 20mM Tris pH 7.2, 10mM CaCl2, 0.1mM ZnCl2, 0.3M NaCl) 
for 8 hours, then finally 3 step of 8 hours each with Buffer C (20mM Tris pH 7.2, 10mM 
CaCl2, 0.1mM ZnCl2, 0.3M NaCl,). The protein was concentrated upto 5 ml and purified 
by size exclusion chromatography using High LoadTM 16/60 SuperdexTM 75ng 
(Amersham Biosciences) and eluted with 20mM Tris pH 7.2, 10mM CaCl2, 0.1mM 
ZnCl2, 0.3M NaCl and 0.2M AHA. The eluted fractions were checked for purity on 15% 
Gel by SDS-PAGE (Fig. 15) and elution fractions containing MMP-12-Cat were pooled 
and concentrated. The protein yield of well refolded purified protein was estimated about 
100-120 mg/l for Wild type as well the mutants of catalytic domain (Table 1). 
 
MMP12 Hpx & Cat-Hpx (Wild type and Mutants): 
Overnight grown cells were harvested by centrifugation, resuspended in 25% Sucrose, 
50mM Tris-HCl (pH 8), 0.1M NaCl, 0.2M EDTA, 1mM DTT. 5-10 mg Lysozyme was 
added to the resulting suspension and stirred for 15-20 min. at 4°C.  Buffer containing 
2% Triton, 50mM Tris-HCl (pH 8), 0.1M NaCl, 0.2M EDTA, 1mM DTT was added and 
sonicated (7-8 cycles of 30 seconds) and centrifuged at 40000 rpm for 20 minutes at 4°C. 
The pellets were resuspended in 6M Urea, 20mM Tris-HCl (pH 8) and centrifuged. The 
resulting inclusion bodies were solublized in 6M Gdn-HCl, 20mM Tris-HCl (pH 8), 
10mM DTT, and 20mM Cystamine and stirred overnight at 4°C. The insoluble material 
was removed by centrifuging at 9000 rpm for 10 minutes. Protein molecular weight and 
purity was checked on 15% Gel by SDS-PAGE.  
 
Refolding process was done by serial dilution method. The protein was diluted to a final 
concentration of 0.13mg/ml in 6M Gdn-HCl, 20mM Tris-HCl (pH 8), 1mM DTT, and 
0.05% Brij-35 stirred at 4°C for 30-60 minutes and dialysed overnight against Buffer A 
(20mM Tris pH 7.2, 10mM CaCl2, 0.1mM ZnCl2, 0.15M NaCl, 5mM b-mercaptoethanol, 
1mM 2-hydroxyethyl disulfide, 0.05% Brij-35) successively followed by Buffer B 
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(20mM Tris pH 7.2, 10mM CaCl2, 0.1mM ZnCl2, 0.15M NaCl, 1mM 2-hydroxyethyl 
disulfide) for 8 hours, Buffer C (20mM Tris pH 7.2, 10mM CaCl2, 0.05mM ZnCl2, 
0.05M NaCl,) 5 hours and then finally 3 step of 5 hours each with buffer D (20mM Tris 
pH 7.2, 10mM CaCl2). The refolded proteins was loaded on CM Sepharose Column 
(Amersham) (5ml X 2) equilibrated with 20mM Tris pH 7.2, 10mM CaCl2 for the 
removal of Brij and  the  process was carried out at 4°C. The bounded protein was eluted 
by 20mM Tris pH 7.2, 10mM CaCl2, 0.3M NaCl and 0.1M AHA. The protein was 
concentrated upto 5 ml and purified by size exclusion chromatography using High 
LoadTM 16/60 SuperdexTM 75ng (Amersham Biosciences) and eluted with 20mM Tris pH 
7.2, 10mM CaCl2, 0.3M NaCl and 0.2M AHA. The eluted fractions were checked for 
purity on 15% Gel by SDS-PAGE (Fig. 15) and elution fractions containing MMP-12-
CatHpx were pooled and concentrated. The yield of well refolded and purified Hpx and 
Cat-Hpx (Wild type & mutants) domains were estimated about 60-80 mg/l and 80-100 
mg/l respectively (Table 1). 
 
 
 
3.7 Protein Stabilization 
Most of the members of MMP family reported to be very active proteases and have the 
tendency of undergoing the process of autolysis or self degradation (16). Thus, the 
problem of autolysis makes the class of protease an unstable protein for long term 
duration. MMP12 like most of its family member is very active and undergoes a process 
of self degradation in its active form resulting in individual catalytic as well as 
Fig.15. SDS PAGE for different domains 
of MMP12 
F171D, E219A, N268D (Inactive) 
F171D, N268D (Active) 
F171D, E219A (Inactive) 
60-80Wild TypeHpx-like
F171D, E219A (Inactive) 
E219A (Inactive)
F171D (Active)
 
 
 
 
80-100 
Wild Type
 
 
 
Cat-Hpx E219A (Inactive)
F171D (Active)
 
 
120-135 
Wild Type
 
Catalytic 
YIELD (mg/liter)FORMDOMAIN
MMP12
Table1. Different domains of MMP12 (Wild type and 
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hemopexin domain with an almost negligible amount of full length Cat-Hpx if kept for a 
long time. Though use of weak inhibitor like Acetohydroxamate results in a decreased 
activity but not very effective for long duration which is one important requirement of 
some NMR experiments as well as crystallization process. The problem is overcome by 
use of strong inhibitor for MMPs like NNGH but it not recommended for the interaction 
studies. Mutation at active sites with out change in structural conformation is one of the 
best options to work with MMPs. Though the mutation at active site (E219A) results in 
decrease in activity to several orders of magnitude but still the protease is not completely 
inactive and thus not suitable for substrate or ligand interaction studies. In order to 
overcome the problem, during the course of work protocol was standardized to have a 
stable protein for a longer duration. The troubleshoot lies in the replacement of the 
catalytic zinc with any other cadmium resulting in almost deceased protease activity 
without any affect on structural conformation or binding with substrate or ligand. 
Cadmium, one of the most lethal metals for any form of life, placed in same group down 
to that of the zinc in the element periodic table. It is preferable over other metals to 
exchange the catalytic zinc ion in MMPs because of the following facts: 
o It’s in the same group to that of zinc in periodic table, 
o It has the same divalent charge like to that of zinc, 
o When ionized cadmium is almost same size to that of zinc, 
o It doesn’t exhibit catalytic activity. 
 
Thus, taking in account the above mentioned criteria we optimized a protocol to 
exchange the catalytic zinc ion with cadmium ion. Again substitution of the catalytic zinc 
is not an easy method. Extensive dialysis of protein against 1mM cadmium for 3-4 weeks 
results in replacement of zinc with cadmium. Cadmium substitution was carried out by a 
slow dialysis process for 20-25 days. The concentrated protein (25-30µM) was dialyzed 
against buffer E (50mM HEPES, 0.2M AHA, 0.3M NaCl, pH 6.8 passed from Chelex-
100 resin, 10mM CaCl2 and 1mM CdCl2) for 20-25 successive days (7ml of protein 
against 50ml buffer). After the extensive dialysis protein was centrifuge to remove any 
kind of precipitation and then concentrated up to 2 ml. The concentrated protein sample 
was washed 4-5 times with buffer F (20mM  Tris-HCl, 0.2M AHA passed from Chelex-
100 resin, 1mM CdCl2) (2ml concentrated protein diluted up to 10 ml with buffer F and 
concentrated again using centricon) to remove the excess of Cadmium and to exchange 
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the buffer for the NMR sample. The cadmium substituted sample along with mutation at 
active site found to be stable for a longer duration at room temperature as well at 4° C.  
3.8 Sample Preparation 
NMR Sample. The NMR samples for various experiments with zinc or cadmium/cobalt 
substitution were prepared after purification by concentrating the protein and removing 
any precipitation resulting during concentration process. The final protein concentration 
for catalytic domain was 1 mM while 0.5-0.7 mM for Hpx and Cat-Hpx domain. 
 
Crystallization. For MMP12–AHA adduct an aliquot of 2 µl of protein solution (20 mM 
Tris/10 mM CaCl2/0.1 mM ZnCl2/300 mM NaCl/200 mM AHA, pH 8) was mixed with 2 
µl of reservoir buffer (0.1 M Tris·HCl/30% PEG 8000, pH 8). The final protein 
concentration was 1mM. Crystallization was carried out with the hanging drop vapor 
diffusion method at 20°C. 
3.9 Biophysical Characterization 
X-ray crystallography and NMR spectroscopy are the two main techniques that can 
provide structures of macromolecules at atomic resolution. Both techniques are well 
established and play a key role in structural biology as a basis for a detailed 
understanding of molecular functions. Their respective different advantages and 
disadvantages in terms of sample preparation and data collection and analysis make this 
it’s complementary in structural proteomics. X-ray studies usually requires substantial 
investment of time in order to optimize the crystallization conditions and obtain a crystal 
with a good diffraction properties This process can take weeks or months, but once a 
well-diffracting (<2.5Å) crystal is obtained, the structure determination can proceed quite 
quickly. NMR Whereas X-ray crystallography requires single crystal; NMR 
measurements are carried out in solution under conditions that can be as close as possible 
to the physiological state. Some times even if crystal structures are available, additional 
data would be needed to determine the potential biological function of the protein. NMR 
is not only capable of solving protein structures to atomic resolution but also has the 
unique ability to accurately measure the dynamic properties of proteins and can also 
supply information on protein folding and on intra-, as well as, intermolecular 
interactions. Furthermore, the analysis through NMR spectroscopy easily allows the 
characterization under several, different experimental conditions, such as different ionic 
strength and pH. However, the two majors bottlenecks limiting the NMR in structural 
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biology are represent from the long time request for the data analysis and structural 
calculation and the drawback size limit of protein. The current is around 35KDa but 
recent advances in both hardware and experimental design promise to allow the study of 
much larger proteins (17). 
 
Circular Dichroism (CD) Spectroscopy: 
Circular Dichroism (CD) spectroscopy measures differences in the absorption of left-
handed polarized light versus right-handed polarized light which arise due to structural 
asymmetry. In addition, the difference in left and right handed absorbance A (l)-A (r) is 
very small (usually range of 0.0001) corresponding to an ellipticity of a few 1/100
th
 of a 
degree. The CD is a function of wavelength. CD spectra for distinct types of secondary 
structure present in peptides, proteins and nucleic acids are different. The analysis of CD 
spectra can therefore yield valuable information about secondary structure of biological 
macromolecules (18). When this light passes through an optically active sample with a 
different absorbance A for the two components, the amplitude of the stronger absorbed 
component will smaller than that of the less absorbed component. The consequence is 
that a projection of the resulting amplitude now yields an ellipse instead of the usual line. 
The occurrence of ellipticity is called Circular Dichroism; it is not the same as optical 
rotation. Rotation of the polarization plane by a small angle α occurs when the phases for 
the 2 circular components become different, which requires a difference in the refractive 
index n. This effect is called circular birefringence. CD is measured as a quantity called 
mean residue ellipticity, whose units are degrees-cm
2
/dmol. Chiral or asymmetric 
molecules produce a CD spectrum because they absorb left and right handed polarized 
light to different extents and thus are considered to be “optically active”. Biological 
macromolecules such as proteins and DNA are compose of optically active elements and 
because they can adopt different types of three-dimensional structures, each type of 
molecule produces a distinct CD spectrum. Circular Dichroism spectroscopy is 
particularly good for:  
• determining whether a protein is folded, and if so characterizing its secondary 
structure, tertiary structure, and the structural family to which it belongs,  
• comparing the structures of a protein obtained from different sources or 
comparing structures for different mutants of the same protein,  
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• studying the conformational stability of a protein under stress-thermal stability, 
pH stability, and stability to denaturants and how this stability is altered by buffer 
composition or addition of stabilizers or excipients.  
• Determining whether protein-protein interactions alter the conformation of 
protein. If there are any conformational changes, this will result in a spectrum 
which will differ from the sum of the individual components (19).  
 
Secondary structure of a protein can be determined by CD spectroscopy in the “far-UV” 
spectral region (190-250nm). At these wavelengths the chromophore is the peptide bond, 
and the signal arises when it is located in a regular folded environment.  
Alpha helix, beta-sheet and random coil structures each give rises to a characteristic 
shape and magnitude of CD spectrum. The approximate fraction of each secondary 
structure type that is present in any protein can thus be determined by analyzing its far-
UV spectrum as a sum of fractional multiples of such reference spectra for each structural 
type. Like all spectroscopic techniques, the CD signal reflects an average of the entire 
molecular population. Thus, while CD can determine that a protein contains about 50% 
alpha-helix, it cannot determine which specific residues are involved in the alpha helical 
portion (20). 
 
X-ray and protein crystallization: 
X-ray crystallography enables to visualize protein structures at the atomic level and 
enhances our understanding of protein function (21). Specifically it is possible to study 
how proteins interact with other molecules, how they undergo conformational changes, 
and how they perform catalysis in the case of enzymes. In order to see proteins in atomic 
detail we need to work with electro-magnetic radiation with a wavelength of around 0.1 
nm or 1 Å (22). 
 
The diffraction from a single molecule would be too weak to be measurable. So it is 
necessary to use an ordered three-dimensional array of molecules, in other words a 
crystal, to magnify the signal. Even a small protein crystal might contain a billion 
molecules. If the crystal is well ordered, then diffraction will be measurable at high 
angles or high resolution and a detailed structure should result. The X-rays are diffracted 
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by the electrons in the structure and consequently the result of an X-ray experiment is a 
3-dimensional map showing the distribution of electrons in the structure (23).  
 
X-ray studies usually require substantial investment of time in order to optimize the 
crystallization conditions and obtain a crystal with good diffraction properties. This 
process can take weeks or months, but once a well-diffracting (<2.5Å) crystal is obtained; 
the structure determination can proceed quite quickly. In order to crystallize a protein, the 
purified protein undergoes slow precipitation from an aqueous solution (24). The 
production of good crystals is dependent upon a number of environmental factors because 
so much variation exists among proteins, with each individual requiring unique condition 
for successful crystallization. Especially protein purity and pH conditions are very 
important; for example different pH values can result in different packing orientations.  
 
The two most commonly used methods for protein crystallization are both vapor 
diffusion techniques. These are known as the “hanging drop” and “sitting drop” methods 
(25). Both entail a droplet containing purified protein, buffer and precipitant being allowed 
to equilibrate with a larger reservoir containing similar buffers and precipitants in higher 
concentrations. Initially, the droplet of protein solution contains an insufficient 
concentration of precipitant for crystallization, but as water vaporizes from the drop and 
transfers to the reservoir, the precipitant concentration increases to a level optimal for 
crystallization. Since the system is in equilibrium, these optimum conditions are 
maintained until the crystallization is complete. 
 
Nuclear Magnetic Resonance (NMR) Spectroscopy: 
Protein nuclear magnetic resonance spectroscopy (usually abbreviated protein NMR) is a 
field of structural biology in which NMR spectroscopy is used to obtain information 
about the structure and dynamics of proteins. Structure determination by NMR 
spectroscopy usually consists of several following phases, each using a separate set of 
highly specialized techniques. The sample is prepared, resonances are assigned, restraints 
are generated and a structure is calculated and validated. 
Protein NMR utilizes multidimensional nuclear magnetic resonance experiments to 
obtain information about the protein. Ideally, each distinct nucleus in the molecule 
experiences a distinct chemical environment and thus has a distinct chemical shift by 
50
 
which it can be recognized. However, in large molecules such as proteins the number of 
resonances can typically be several thousand and a one-dimensional spectrum inevitably 
has incidental overlaps. Therefore multidimensional experiments are performed which 
correlate the frequencies of distinct nuclei. The additional dimensions decrease the 
chance of overlap and have larger information content since they correlate signals from 
nuclei within a specific part of the molecule. Pulse sequences allow the experimenter to 
investigate and select specific types of connections between nuclei. Depending on the 
concentration of the sample, on the magnetic field of the spectrometer, and on the type of 
experiment, a single multidimensional nuclear magnetic resonance experiment on a 
protein sample may take hours or even several days to obtain suitable signal-to-noise 
ratio through signal averaging, and to allow for sufficient evolution of magnetization 
transfer through the various dimensions of the experiment. Other things being equal, 
higher-dimensional experiments will take longer than lower-dimensional experiments. 
Typically the first experiment to be measured with an isotope-labeled protein is a 2D 
heteronuclear single quantum correlation (HSQC) spectrum where "heteronuclear" refers 
to nuclei other than 1H. In theory the heteronuclear single quantum correlation has one 
peak for each H bound to a heteronucleus (26). Thus in the 15N-HSQC one signal is 
expected for each amino acid residue with the exception of proline which has no amide-
hydrogen due to the cyclic nature of its backbone. The 15N-HSQC is often referred to as 
the fingerprint of a protein because each protein has a unique pattern of signal positions. 
With unlabelled protein the usual procedure is to record a set of two dimensional 
homonuclear nuclear magnetic resonance experiments through correlation spectroscopy 
(COSY), of which several types include conventional correlation spectroscopy, total 
correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy 
(NOESY)(27, 28). A two-dimensional nuclear magnetic resonance experiment produces a 
two-dimensional spectrum. The units of both axes are chemical shifts. The COSY and 
TOCSY transfer magnetization through the chemical bonds between adjacent protons. 
The process of resonance assignment for a nitrogen-15 labeled sample is similar to the 
homonuclear case. No experiment can be performed that transfers magnetization between 
two spin systems through bonds either. The main difference is the ability to record 
nitrogen-15 edited three dimensional experiments: TOCSY-N HSQC and NOESY-N-
HSQC. These experiments build onto the HSQC experiment, but have an additional 
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proton dimension. It can be visualised as each peak in the HSQC having the TOCSY or 
NOESY peaks stacked onto it. Thus if the TOCSY peak from an amide proton, HN, has a 
cross peak to its alpha proton, Halpha, at the coordinates (HN, Halpha) in the TOCSY 
spectrum, the corresponding peak would be at (HN, Halpha,N) in the TOCSY-N-HSQC. 
Thus it is possible to resolve overlaps in the proton dimension, if the corresponding 
nitrogen has chemical shifts distinct from one another. When the protein is labeled with 
carbon-13 and nitrogen-15 it is possible to record an experiment that transfers 
magnetization over the peptide bond, and thus connect different spin systems through 
bonds. This is usually done using some of the following experiments, HNCO, HNCACO, 
HNCA, HNCOCA, HNCACB and CBCACONH (29, 30). All six experiments consist of a 
HSQC plane expanded with a carbon dimension. In the HNCACO the spectrum contains 
peaks at the chemical shifts of the carbonyl carbons in the residue of the HSQC peak and 
the previous one in the sequence. The HNCO only contains the chemical shift from the 
previous residue, and it is thus possible to assign the carbonyl carbon shifts that 
correspond to each HSQC peak and the one previous to that one. Sequential assignment 
can then be undertaken by matching the shifts of each spin system's own and previous 
carbons. The HNCA and HNCOCA work similarly, just with the alpha carbons rather 
than the carbonyls, and the HNCACB and the CBCACONH contains both the alpha 
carbon and the beta carbon. Usually several of these experiments are required to resolve 
overlap in the carbon dimension. This procedure is usually less ambiguous than the 
NOESY based method, since it is based on through bond transfer. In the NOESY-based 
methods additional peaks that are close in space but not belonging to the sequential 
residues will appear confusing the assignment process. When the sequential assignment 
has been made it is usually possible to assign the side-chains using HCCH-TOCSY, 
which is basically a TOCSY experiment resolved in an additional carbon dimension. 
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Abstract: The proteolytic activity of matrix metalloproteinases toward extracellular matrix components (ECM),
cytokines, chemokines, and membrane receptors is crucial for several homeostatic and pathological
processes. Active MMPs are a family of single-chain enzymes (23 family members in the human genome),
most of which constituted by a catalytic domain and by a hemopexin-like domain connected by a linker.
The X-ray structures of MMP-1 and MMP-2 suggest a conserved and well-defined spatial relationship
between the two domains. Here we present structural data for MMP-12, suitably stabilized against self-
hydrolysis, both in solution (NMR and SAXS) and in the solid state (X-ray), showing that the hemopexin-
like and the catalytic domains experience conformational freedom with respect to each other on a time
scale shorter than 10-8 s. Hints on the probable conformations are also obtained. This experimental finding
opens new perspectives for the often hypothesized active role of the hemopexin-like domain in the enzymatic
activity of MMPs.
Introduction
Matrix metalloproteinases (MMP) are an important family
of 23 proteins which are involved in a number of extracellular
processes1–3 including the degradation of the extracellular
matrix.4 The latter is constituted by structural proteins such as
collagen and elastin, by proteoglycans, and by adhesive proteins
such as fibronectin, laminin, and tenascin.5 MMPs are single-
chain enzymes secreted by cells as inactive proenzymes. The
active form is liberated outside the cell by the cleavage of the
prodomain by other proteases, including MMPs themselves,6,7
thereby implying a complex regulation mechanism which also
involves other proteins such as tissue inhibitors of MMPs (called
TIMPs).8,9
All active MMPs but MMP-7 are constituted by two domains,
a catalytic (CAT) and a hemopexin-like (HPX) domain. The
CAT and HPX domains are connected by a linker whose length
varies from 14 to 68 AA.10,11 For many MMPs the linker is
relatively short (14-23 AA) whereas for MMP-9 and MMP-
15, at the other extreme, the intervening residues between the
CAT and HPX domains (68 and 63 AA, respectively) constitute
a further, highly glycosylated, domain termed OG domain.12,13
The CAT domain alone bears full proteolytic activity toward a
range of peptides and proteins.14–17 However, efficient pro-
teolysis of, for instance, triple helical collagen requires the full-† CERM, University of Florence.
‡ Department of Chemistry, University of Florence.
§ Department of Agricultural Biotechnology, University of Florence.
| Hamburg Outstation.
⊥ Russian Academy of Sciences.
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length active protein.18,19 For this reason, it is often hypothesized
that the HPX domain helps the local unwinding of the triple
helix, in such a way that a single peptide strand can be
accommodated in the active site of the CAT domain and
cleaved.20,21 It has been also hypothesized that a relative
mobility of the HPX domain is necessary for this function.22–25
This seems to be the case for MMP-9, for which small-angle
X-ray scattering (SAXS) and atomic force microscopy (AFM)
experiments indicate that the OG domain is able to lose its
globular shape and transiently assume elongated structures,
thereby allowing relative motion of the CAT and HPX do-
mains.26 On the other hand, X-ray structures of the full-length
proenzyme forms of other MMPs lacking the OG domain
display a well-defined structural relationship between the CAT
and HPX domains, and this relationship is the same in the two
different pro-MMPs studied (i.e., pro-MMP-125 (14 AA linker)
and pro-MMP-227 (20 AA linker)).25 The structures of active
MMP-1,28 and of its porcine ortholog,29 are also compact and
show a slightly different orientation of the HPX domain with
respect to pro-MMP. This difference, although small, has been
highlighted as evidence of the potential ability of the HPX
domain to move with respect to the CAT domain.25,28
Here we have addressed the general problem of the relative
conformational freedom of the two domains of MMPs in
solution by NMR. NMR in solution is a powerful tool to
investigate internal mobility of biomolecules30–42 and can also
provide precious information on interprotein and interdomain
mobility.43–49
We selected MMP-12 (16 AA linker), for which an extended
NMR assignment of the CAT domain is available, as well as
high-resolution solid state and NMR structures. In this work,
we have assigned the NMR signals of the HPX domain, solved
its solution structure, and assigned the full-length protein. We
have then obtained relaxation data (R1, R2, NOE) for the full-
length protein and compared it with the same data for its isolated
CAT and HPX domains. These data show that the two domains
are not held rigidly to one another but must undergo independent
motions. Residual dipolar couplings (RDC) on the full-length
protein in the presence of an external orienting device were also
obtained and found inconsistent with a rigid conformation of
the protein.
Repeated attempts to crystallize full-length MMP-12 for X-ray
diffraction finally yielded crystals of modest quality, which
diffracted to 3 Å resolution. This low resolution was, however,
largely sufficient to establish that the structure is less compact
and the relative orientation of the two domains totally different,
with respect to the four X-ray structures of MMP-1 and MMP-2
already described. Small-angle X-ray scattering (SAXS) data
are consistent with the determined structure in the crystal
representing the major conformation in solution but also point
to a conformational mobility of the domains in MMP-12.50
Materials and Methods
Protein Expression. The cDNA encoding the G106-C470
sequence of full-length MMP-12 was generated by a polymerase
chain reaction (PCR) from an IMAGE consortium clone using two
synthetic oligonucleotides as primers. The cDNA obtained was
cloned into the pET21a (Novagen) using the restriction enzymes
Nde I and Xho I (New England BioLabs). One additional methionine
at position 105 was present in the final expression product.
The expression vector encoding for the full-length protein (FL-
MMP-12) was transformed into competent Escherichia coli BL21
(DE3) Codon Plus strain, and colonies were selected for Ampicillin
and chloramphenicol resistance. Bacteria were grown in LB medium
containing 34 µg/mL chloramphenicol and 50 µg/mL ampicillin in
a shaker flask at 37 °C. Protein expression was induced with 0.5
mM IPTG at an OD600 ) 0.6, and cell growth was continued for a
further 5 h. For expression of 15N and 13C-enriched FL-MMP-12,
the bacteria were grown in minimal medium containing 15N
enriched (NH4)2SO4 and 13C enriched glucose (Cambridge Isotope
Laboratories). Cells were harvested by centrifugation and resus-
pended in a buffer containing 25% sucrose, 50 mM Tris-HCl (pH
8), 0.1 M NaCl, 0.2 M EDTA, 1 mM DTT. Five to ten milligrams
of lysozyme were added to the resulting suspension and stirred for
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15-20 min at 4 °C. A buffer containing 2% Triton, 50 mM Tris-
HCl (pH 8), 0.1 M NaCl, 0.2 M EDTA, and 1 mM DTT was added,
and the suspension was sonicated (7-8 30 s cycles) and centrifuged
at 40 000 rpm for 20 min at 4 °C. The pellets were resuspended in
6 M Urea, 20 mM Tris-HCl (pH 8) and centrifuged. The resulting
inclusion bodies were solubilized in 6 M Gdn-HCl, 20 mM Tris-
HCl (pH 8), 10 mM DTT, and 20 mM cystamine and stirred
overnight at 4 °C. The insoluble material was removed by
centrifuging at 9000 rpm for 10 min. Protein molecular weight and
purity was checked on 15% gel by SDS-PAGE. The F171D, E219A
mutant of FL-MMP-12 was produced using the quick-change site-
directed mutagenesis kit (Qiagen), and the expression and purifica-
tion of the protein and of its 15N- and 13C-15N-enriched versions
completed using the same procedure described above.
Refolding was carried out by a serial dilution method.51 The
protein was diluted to a final concentration of 0.13 mg/mL in 6 M
Gdn-HCl, 20 mM Tris-HCl (pH 8), 1 mM DTT, and 0.05% Brij-
35, stirred at 4 °C for 30-60 min, and dialyzed overnight against
a buffer containing 20 mM Tris (pH 7.2), 10 mM CaCl2, 0.1 mM
ZnCl2, 0.15 M NaCl, 5 mM -mercaptoethanol, 1 mM 2-hydroxy-
ethyl disulfide, and 0.05% Brij-35. The refolded protein was then
purified using a Sepharose column (Amersham) with a buffer
containing 20 mM Tris (pH 7.2), 10 mM CaCl2, 0.3 M NaCl and
0.1 M acetohydroxamic acid (AHA). The protein solution was
concentrated up to 5 mL and purified by size exclusion chroma-
tography using a High Load 16/60 Superdex 75 (Amersham
Biosciences) and eluted with 20 mM Tris pH 7.2, 10 mM CaCl2,
0.3 M NaCl, and 0.2 M AHA. The eluted fractions were checked
for purity on 15% gel by SDS-PAGE, and those containing the
FL-MMP-12 protein were pooled and concentrated.
Samples of cadmium(II) substituted FL-MMP-12 protein were
prepared by exhaustive dialysis against a buffer containing 20 mM
Tris pH 7.2, 10 mM CaCl2, 0.3 M NaCl, 0.2 M AHA, and 0.3 mM
of CdCl2.52 Equimolar concentrations of N-isobutyl-N-[4methox-
yphenylsulfonyl] glycyl hydroxamic acid (NNGH) were added to
the samples to further increase the protein stability.
The cDNA encoding for the HPX domain (E278-C470) was
generated by polymerase chain reaction and cloned into pET21a,
using Nde I and Xho I as restriction enzymes. The expression vector
was then transformed into competent E. coli BL21 (DE3) Gold
strain, and the colonies were selected for Ampicillin resistance.
Protein refolding for both nonlabeled and for 13C and/or 15N
enriched samples was carried out by using the same protocols
previously described for the preparation of FL-MMP-12 samples.
Samples of the zinc(II) catalytic domain (F171D mutant) were
prepared as previously described.50
NMR Measurements and Solution Structure Calculations.
The experiments for the structure calculation and mobility measure-
ments of the isolated HPX domain were performed on protein
samples at concentrations ranging between 0.5 and 0.7 mM (pH
7.2). For FL-MMP-12, all NMR experiments were performed on
samples at a concentration of 0.5 mM (pH 7.2).
All NMR experiments were performed at 298 K and acquired
on Bruker AVANCE 900, AVANCE 800, AVANCE 700 and DRX
500 spectrometers. All instruments but one are equipped with triple
resonance CRYO-probes. The 700 MHz spectrometer is equipped
with a triple resonance (TXI) 5 mm probe with a z-axis pulse field
gradient.
All spectra were processed with the Bruker TOPSPIN software
packages and analyzed by the program CARA (Computer Aided
Resonance Assignment, ETH Zu¨rich).53
The backbone resonance assignment was obtained by the analysis
of HNCA, HNCO, HN(CA)CO, HNCACB, and CBCA(CO)NH
spectra performed at 900 MHz. The assignment of the aliphatic
side-chain resonances was performed through the analysis of 3D
(H)CCH-TOCSY spectra at 500 MHz, together with 3D 15N- and
13C-NOESY-HSQC spectra at 900 MHz. The obtained assignments
are reported in Tables S1 and S2 for the full length protein and
tables S3 and S4 for the hemopexin domain. 3JHNHR coupling
constants were determined through the HNHA experiment at 500
MHz. Backbone dihedral  angles were independently derived from
3JHNHR coupling constants through the appropriate Karplus equa-
tion.54 Backbone dihedral ψ angles for residue i-1 were also
determined from the ratio of the intensities of the dRN(i-1,i) and
dNR(i,i) NOEs present on the 15N(i) plane of residue i obtained from
the 15N-edited NOESY-HSQC spectrum.
3D 15N- and 13C-enriched NOESY-HSQC cross peak intensities
were integrated using the integration routine implemented in CARA
and converted into interatomic upper distance limits by the program
CALIBA.55
The protein assignment and the mobility measurements on FL-
MMP-12 where performed on the NNGH-inhibited, cadmium(II)-
substituted Phe171Asp/Glu219Ala mutant, due to its high stability
to the self-hydrolysis. Mobility measurements on the catalytic
domain where performed on the NNGH-inhibited, zinc(II) form of
the Phe171Asp mutant.50
Residual dipolar couplings have been measured on FL-MMP-
12 in the presence of an external orienting medium constituted by
a binary mixture of C12E5 (penta-ethyleneglycol dodecyl ether,
Fluka) and neat n-hexanol (Fluka), with a molar ratio C12E5/n-
hexanol of 0.96 and with a C12E5/water ratio of 5 wt %.56 One-
bond 1H-15N coupling constants were measured at 298 K and 900
MHz by using the IPAP method.57,58 Two-hundred fifty-nine rdc
values could be measured that ranged from -46 to +25 Hz. Of
them, only those rdc values corresponding to residues experiencing
neither mobility nor large rmsd (140 residues, mostly in R or 
secondary structures, see Table S5, Supporting Information) have
been used for structure calculations and to investigate the reciprocal
mobility of the two domains.
The program DYANA59 was used to calculate a family of 1600
structures of the isolated HPX domain starting from randomly
generated conformers in 20 000 annealing steps. The solution
structure statistics are reported in Table S6 (Supporting Informa-
tion). The family was energy-minimized by iterative cycles of
DYANA with the program FANTAORIENT.60 The quality of the
structures calculated by DYANA can be assessed by a properly
defined energy function (target function) proportional to the squared
deviations of the calculated constraints from the experimental ones,
plus the standard covalent and nonbonded energy terms. Structure
calculation statistics and the structural quality were evaluated using
the program PROCHECK_NMR.61
R1, R2, and NOE Measurements. The experiments for the
determination of 15N longitudinal and transverse relaxation rates
and 1H-15N NOE were recorded at 298 K and 700 MHz on 15N-
enriched samples. The 15N longitudinal relaxation rates (R1) were
measured using a sequence modified to remove cross correlation
effects during the relaxation delay.62 Inversion-recovery times
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ranging between 2.5 and 3000 ms, with a recycle delay of 3.5 s,
were used for the experiments. The 15N transverse relaxation rates
(R2) were measured using a CPMG sequence62,63 with delays
ranging between 8.5 and 237.4 ms for the CAT domain, between
8.5 and 203.5 ms for the HPX domain, and finally between 8.5
and 135.7 ms for the FL-MMP-12 protein with a refocusing delay
of 450 µs. The relaxation data are reported in Table S7 (Supporting
Information). R1 and R2 data measured on the full length protein
were found nosier and less uniform with respect to those of the
single catalytic and hemopexin domains. This is related to the
overlap of the signals in a so large protein and to the relative low
solubility of the full length construct.
Crystallization, Data Collection, and X-ray Structure
Determination. Crystals of the zinc(II) Phe171Asp/Glu219Ala
FL-MMP-12 were obtained using the vapor diffusion technique at
20 °C from a solution containing 0.1 M Tris-HCl, 30% PEG-8000,
200 mM AHA, pH 8.0. The final protein concentration was
0.7 mM.
The data collection was carried out in-house, using a PX-Ultra
copper sealed tube source (Oxford Diffraction) equipped with an
Onyx CCD detector. The data set was collected at 100 K and the
crystals used for data collection were cryo-cooled using a solution
containing 10% ethylene glycol in the mother liquor.
The crystal diffracted to 3.0 Å resolution; it belongs to space-
group C2 with one molecule in the asymmetric unit, a solvent
content of about 50%, and a mosaicity of about 1.0°.
The data was processed using the program MOSFLM64 and
scaled using the program SCALA65 with the TAILS and SEC-
ONDARY corrections on (the latter restrained with a TIE SUR-
FACE command) to achieve an empirical absorption correction.
The structure was solved using the molecular replacement technique
in two following steps; in the first step, the model used to find the
correct orientation of the catalytic part of the structure was 1Y93
whereas the one used for the hemopexin domain was the same
domain in proMMP-1 structure (1SU3). In both steps, inhibitors,
water molecules, and ions were omitted from the models.
The correct orientation and translation of the molecules within
the crystallographic unit cell was determined with standard Patterson
search techniques66,67 as implemented in the program MOLREP.68,69
The isotropic refinement was carried out using REFMAC570 and
default weights for the crystallographic term and the geometrical
term were used.
In between the refinement cycles, the models were subjected to
manual rebuilding by using XtalView.71 The same program was
used to model AHA molecule. Water molecules have been added
by using the standard procedures within the ARP/WARP suite.72
The stereochemical quality of the refined models was assessed using
the program PROCHECK.73 The Ramachandran plot is of average
quality for such a resolution structure. Of the seven violations four
(Asp303, Ser311, Lys315, and Asn363) are located in the he-
mopexin domain; it is interesting to compare these outliers to the
equivalent residues in MMP-1 (1SU3) which has a higher resolution
(2.2 Å). Asp299 (corresponding to Asp303 in MMP-12) is an outlier
as well, and in the place of Ser311 there is a proline residue
(Pro307) which has of course a unique stereochemistry; furthermore
in the place of Asn363 there is Gly359 in MMP-1, which again is
unique from the stereochemical point of view. Therefore, three out
of the four residues that are in disallowed regions in the HPX
domain may actually assume peculiar positions in the 3-D structure.
Table S8 (Supporting Information) reports the data collection and
refinement statistics.
SAXS Experiments and Data Analysis. Synchrotron X-ray
scattering data from solutions of the NNGH-inhibited, cadmium(II)-
substituted Phe171Asp/Glu219Ala double mutant of FL-MMP-12
were collected on the X33 beamline of the EMBL (DESY,
Hamburg),74 using a MAR345 image plate detector. The scattering
patterns were measured with a 2 min exposure time for several
solute concentrations in the range from 0.8 to 8.3 mg/mL. To check
for radiation damage, two 2 min exposures were compared, and
no changes were detected. Using the sample-detector distance of
2.7 m, a range of momentum transfer of 0.01 < s < 0.5 Å-1 was
covered (s ) 4π sin(θ)/λ, where 2θ is the scattering angle, and
λ ) 1.5 Å is the X-ray wavelength). The data were processed using
standard procedures and extrapolated to infinite dilution using the
program PRIMUS.75 The forward scattering, I(0), and the radius
of gyration, Rg, were evaluated using the Guinier approximation,76
assuming that at very small angles (s < 1.3/Rg) the intensity is
represented as I(s) ) I(0) exp(-(s2Rg2)/3. The values of I(0) and
Rg, as well as the maximum dimension, Dmax, and the interatomic
distance distribution functions, (p(r)), were also computed using
the program GNOM.77 The molecular mass of FL-MMP-12 was
evaluated by comparison of the forward scattering with that for a
reference solution of bovine serum albumin (66 kDa).
The scattering from the high resolution models was computed
using the program CRYSOL.78 Given the atomic coordinates, the
program either predicts the theoretical scattering pattern or fits
the experimental intensity by adjusting the excluded volume of the
particle and the contrast of the hydration layer to minimize the
discrepancy
x
2 ) 1N- 1∑i [Iexp(Sj)- cIcalc(Sj)σ(Sj) ]2 (1)
where N is the number of experimental points, c is a scaling factor,
Iexp(sj) and Icalc(sj) are the experimental and calculated intensities,
respectively, and σ(sj) is the experimental error at the momentum
transfer sj.
To assess the conformational variability of MMP-12, an ensemble
optimization method (EOM) was used,79 allowing for coexistence
of multiple conformations in solution. About 5000 randomized
models of MMP-12 differing by the conformation of the interdo-
main linker were generated using the program DYANA starting
from randomly generated conformers of the full-length protein
where only the dihedral angles of the linker region were left free
to vary. These models formed a pool of possible structures, for
which the scattering patterns were computed by CRYSOL. The
EOM program employs a genetic algorithm to select from the pool
a small number (usually about 20) of representative structures such
that the average scattering from the selected ensemble fits the
experimental data. Multiple runs of EOM were performed and
the results were averaged to provide quantitative information about
(63) Peng, J. W.; Wagner, G. Methods Enzymol. 1994, 239, 563–596.
(64) Leslie, A. G. W. In Molecular data processing; Moras, D., Podjarny,
A. D., Thierry, J.-C., Eds.; Oxford University Press: Oxford, 1991;
pp 50-61.
(65) Evans, P. R. Joint CCP4 and ESF-EACBM Newsletter 1997, 33,
22–24.
(66) Rossmann, M. G.; Blow, D. M. Acta Crystallogr. 1962, 15, 24.
(67) Crowther, R. A. The Molecular Replacement Method; Rossmann,
M. G., Ed.; Gordon & Breach: New York, 1972.
(68) Vagin, A.; Teplyakov, A. J. Appl. Crystallogr. 1997, 30, 1022–1025.
(69) Vagin, A.; Teplyakov, A. Acta Crystallogr. D: Biol. Crystallogr.
2000, 56, 1622–1624.
(70) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Acta Crystallogr.
1997, D53, 240–255.
(71) McRee, D. E. J. Mol. Graphics 1992, 10, 44–47.
(72) Lamzin, V. S. Acta Crystallogr. D: Biol. Crystallogr. 1993, 49, 129–
147.
(73) Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M.
J. Appl. Crystallogr. 1993, 26, 283–291.
(74) Roessle, M. W.; Klaering, R.; Ristau, U.; Robrahn, B.; Jahn, D.;
Gehrmann, T.; Konarev, P. V.; Round, A.; Fiedler, S.; Hermes, S.;
Svergun, D. I. J. Appl. Crystallogr. 2007, 40, s190–s194.
(75) Konarev, P. V.; Volkov, V. V.; Sokolova, A. V.; Koch, M. H. J.;
Svergun, D. I. J. Appl. Crystallogr. 2003, 36, 1277–1282.
(76) Guinier, A. Ann. Phys. 1939, 12, 161–237.
(77) Svergun, D. I. J. Appl. Crystallogr. 1992, 25, 495–503.
(78) Svergun, D. I.; Barberato, C.; Koch, M. H. J. J. Appl. Crystallogr.
1995, 28, 768–773.
(79) Bernado, P.; Mylonas, E.; Petoukhov, M. V.; Blackledge, M.;
Svergun, D. I. J. Am. Chem. Soc. 2007, 129, 5656–5664.
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the flexibility of the protein in solution (in particular, about the Rg
distribution in the selected ensembles).
Results and Discussion
Design and Production of a Stable Full-Length MMP-12.
Several MMPs, both as isolated catalytic domains (CAT) or
full-length (FL) proteins, are relatively unstable in Vitro due to
self-proteolysis (while the inactive isolated hemopexin domain
(HPX) is stable). In the case of MMP-12, the CAT domain can
be stabilized by a Phe171Asp mutation that prevents self-
proteolysis and increases the solubility. This mutation is far both
from the active site and from the CAT-HPX interface (see later)
and does not perturb the catalytic activity of the enzyme.
Therefore, a FL construct with the Phe171Asp mutation was
initially produced. The resulting protein was well folded and
fully active but still sensitive to the self-proteolysis at the linker
region even in the presence of the inhibitor NNGH.
To increase the stability, the catalytically relevant Glu219
was mutated to an Ala. This mutation had been shown to
decrease the catalytic activity of the isolated CAT domain of
MMPs by two-3 orders of magnitude,80 whereas the three-
dimensional structure of the domain is fully retained.81 The
Phe171Asp/Glu219Ala double mutant of the FL protein was
stable for several days.
Finally, we substituted the catalytic zinc(II) ion, responsible
for the residual activity, with a cadmium(II) ion. The resulting
derivative, complexed with NNGH, resulted stable to proteoly-
sis, showing no trace of cleaved CAT and HPX domains in the
gel after three weeks of NMR measurements. The analysis of
the HSQC spectra revealed that no structural alteration were
caused by the replacement of zinc(II) with the cadmium(II) ion.
The NNGH-inhibited, cadmium(II)-substituted Phe171Asp/
Glu219Ala double mutant of FL-MMP-12 was therefore used
in all NMR experiments reported hereafter.
Low-Resolution X-Ray Structure of FL-MMP-12 and
Comparison with Existing Structural Information on
FL-MMP. Crystals diffracting at 3.0 Å were obtained for the
AHA-inhibited, zinc(II) Phe171Asp/Glu219Ala double mutant
of FL-MMP-12.
The X-ray structure of this construct was solved from
diffraction data obtained in-house and deposited in PDB (PDB
code: 3BA0). Despite the low resolution, the electron density
was of generally good quality throughout the entire molecule,
the only exception being residues 271-274 in the middle of
the linker region (see below), which spans from Asp264 to
Pro279. The overall structure of the CAT domain is very similar
to the high resolution structure of the isolated CAT domain.50
The mutations are both clearly visible; the active site contains
both the native catalytic zinc ion and the structural zinc ion.
Three calcium atoms are also present in the structure of the
CAT domain. Finally, a AHA molecule bound to the zinc ion
in the usual geometry50 is present at the active site. The HPX
domain has the expected four-blade propeller, hemopexin-like
foldpreviouslyobservedinotherHPXdomainsofMMPs.22,25,27,29,82–85
The disulfide bridge between Cys282 and Cys470 is clearly
present, and a calcium ion is bound in the central region of the
domain.
The relative orientation of the two domains could be
unambiguously determined from the 3 Å X-ray data (Figure
1A). The two domains are in contact through a relatively small
surface (∼165 Å2) which includes a possible salt bridge between
His112 of CAT domain and the C-terminal of Cys470 in the
HPX domain, and van der Waals interactions between residue
113 of CAT and residues 284 and 463 on the HPX side. The
first part of the linker (residues 264, 265, 266, 270, 271, and
273) is in touch with the CAT domain (residues 112, 143, 144,
249, 259, and 263) through a surface of 902 Å2 and the last
part (residues 277 and 279) with the HPX domain (residues
280, 307, and 470) through a surface of 571 Å2 (Figure 1A).
Furthermore, the linker residue Lys266, besides being in contact
with the CAT domain, forms a salt bridge with the C-terminal
of HPX domain. The central part of the linker (residues
271-274) shows a rather poor electron density, but its structure
can be reasonably modeled to match the arrangement of the
initial and final linker residues. It is apparent that the whole
molecule is held together mainly by interactions between each
single domain and the linker rather than between the two
domains. The presence of the intact linker was confirmed by a
gel experiment on a protein solution obtained after redissolving
crystals collected from the same wells of those used for X-ray.
Figure 1C shows a superposition of the X-ray structures of
human proMMP-1 and proMMP-2, the only FL-proMMPs
structures available to date, where the prodomain and the
fibronectin domains (in case of MMP-2) have been omitted for
clarity. The CAT-HPX interface is very similar in the two
proteins and relatively extended (ca. 753 and 866 Å2, respec-
tively, as opposed to ca. 165 Å2 in FL-MMP-12), suggestive
of a stable domain-domain interaction. Figure 1D shows a
superposition of the structures of active human FL-MMP-128
and of its porcine ortholog.29 Again, the two structures are very
similar, and the CAT-HPX interface is again extended (ca. 735
and 747 Å2, respectively). The relative orientation of the HPX
domain is slightly different in these active forms with respect
to the pro-enzyme forms (cfr. Figure 1D and 1C, where the
CAT domain has the same orientation), as previously noticed.28
Relative to the CAT domain, the HPX domain in FL-MMP-
12 lies at about 120° with respect to its orientation in the
structures of MMP-1 and MMP-2 (Figure 1E), and the two
domains have a less compact arrangement (cfr. Figure 1A and
1B). The interface region is completely different, both viewed
from the CAT and from the HPX domain, is sensibly smaller
(ca. 165 vs 735-866 Å2), and the complementarity between
the surfaces of the two domains is poor with respect to that
observed in the experimental structures of FL-MMP-1 and FL-
MMP-2.
NMR Characterization of FL-MMP-12. The NNGH-inhib-
ited, cadmium(II)-substituted Phe171Asp/Glu219Ala double
mutant of FL-MMP-12 (FL-MMP-12 hereafter) yields 15N-1H
HSQC spectra of surprisingly good quality for a protein of
42 000 Da (see Figure 2A) (spectra of this type were obtained
on all constructs of FL-MMP-12 described before).
Figure 2B shows the 15N-1H HSQC spectrum of FL-MMP-
12 (in black) superimposed to those of the isolated CAT domain
(in green), prepared as previously reported, and of the isolated
HPX domain (in red, see below). The similarity is striking:
except for a number of peaks that are not present in either the
(80) Cha, J.; Auld, D. S. Biochemistry 1997, 36, 16019–16024.
(81) Bertini, I.; Calderone, V.; Fragai, M.; Luchinat, C.; Maletta, M.; Yeo,
K. J. Angew. Chem., Int. Ed. 2006, 45, 7952–7955.
(82) Morgunova, E.; Tuuttila, A.; Bergmann, U.; Tryggvason, K. Proc.
Natl. Acad. Sci. U.S.A. 2002, 99, 7414–7419.
(83) Libson, A. M.; Gittis, A. G.; Collier, I. E.; Marmer, B. L.; Goldberg,
G. I.; Lattman, E. E. Nat. Struct. Biol. 1995, 2, 938–942.
(84) Gohlke, U.; Gomis-Ruth, F. X.; Crabbe, T.; Murphy, G.; Docherty,
A. J.; Bode, W. FEBS Lett. 1996, 378, 126–130.
(85) Cha, H.; Kopetzki, E.; Huber, R.; Lanzendorfer, M.; Brandstetter,
H. J. Mol. Biol. 2002, 320, 1065–1079.
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isolated CAT and HPX domains, which must therefore belong
to the linker, all other FL-MMP-12 peaks are superimposable,
or nearly superimposable, to a peak of either the isolated CAT
or HPX domain. Furthermore, the peaks of FL-MMP-12 were
only marginally broader that the corresponding peaks in the
isolated domains.
The 13C, 15N, and 1H spectral assignment of the CAT domain
was available,50 whereas that of the HPX domain was performed
during this research. Also the solution structure of the HPX
domain, up to now unavailable for MMP-12, was experimentally
solved here (see Table S6 and Figure S1, Supporting Informa-
tion) and deposited in PDB (PDB code: 2JXY). Ribbon
representations of the solution and crystal structures are reported
in Figure S1. The relatively high rmsd between the two
structures (BB ) 1.88 Å, secondary structure elements ) 1.16
Å) is within the indetermination of both the X-ray (3.0 Å
resolution) and NMR structures (BB rmsd ) 1.38 Å, heavy atom
rmsd ) 2.13 Å).
The 15N-1H HSQC spectrum of FL-MMP-12 could be
largely assigned by direct comparison with the isolated CAT
and HPX spectra. Nevertheless, 97% of the nonlinker residues
were reassigned by recording the same set of 3D spectra used
for the structure of the isolated domains. Despite the crowding,
the spectra were of good enough quality to assign most of the
backbone atoms of the two domains as well as a large fraction
of side-chain atoms (Table S1, Supporting Information). 3D
NOESY spectra were also recorded. The NOESY patterns were
largely the same as those observed in the isolated CAT and
HPX domains, indicating that the domain structures are indeed
unaltered in the FL protein, as it was already apparent from the
comparison of the HSQC spectra. No interdomain NOEs could
be found. The largest difficulties in the assignment were
encountered in the linker region. Although several of the linker
15N-1H HSQC peaks could be identified as the extra peaks
present in the FL protein spectra and not corresponding to peaks
of any of the two domains, several of the necessary sequential
connectivities were missing in the 3D spectra. In addition, very
few NOEs could be seen for these peaks. A protonless CON
experiment86 allowed us to identify two of the linker prolines.
Ten linker peaks could be identified, and four of them sequence-
specifically assigned (Table 1).
Relaxation Data. The 700 MHz R1 and R2 data for FL-MMP-
12 as well as for the isolated CAT and HPX domains are shown
in Figure 3A-D. R1 and R2 values can be accurately estimated
from the atomic coordinates of a macromolecule of known
structure assuming a rigid-body hydrodynamics by using
computer programs like HYDRONMR.87 In this study, the
X-ray structure of the CAT domain (PDB code: 1Y93),50 the
present solution structure of the HPX domain, and the present
X-ray structure of the full length protein (Figure 1E) were used
as input files in HYDRONMR. As shown in Figure 3, while
for the isolated domains the experimental data nicely match the
calculated values, for FL-MMP-12 sizably faster longitudinal
and sizably slower transverse relaxation rates with respect to
the calculated values were measured. These differences are
clearly statistically significant, despite the larger errors due to
the signal overlap and lower signal-to-noise ratios in the spectra
(86) Bermel, W.; Bertini, I.; Duma, L.; Emsley, L.; Felli, I. C.; Pierattelli,
R.; Vasos, P. R. Angew. Chem., Int. Ed. 2005, 44, 3089–3092.
(87) de la Torre, J. G.; Huertas, M. L.; Carrasco, B. J. Magn. Reson.
2000, 147, 138–146.
Figure 1. Space-filling representations of the X-ray structures of FL-MMP-12 (A, present work) and FL-MMP-1 (B).28 Superimposition of the X-ray
structures of (C) human pro-MMP-125 (red) and pro-MMP-227 (yellow) (where the prodomain of both and the fibronectin domains of MMP-2 have been
omitted for clarity), (D) human28 (violet) and porcine29 (green) FL-MMP-1, and (E) human FL-MMP-128 (violet) with the present FL-MMP-12 (blue).
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of FL-MMP-12. The R1 and R2 values measured on FL-MMP-
12 are intermediate between the expectation from the isolated
domains and a rigid full length structure. At the same time, the
NOE values for FL-MMP-12 (Figure 3E) demonstrate that the
single domains (catalytic and hemopexin) forming the full length
protein behave as rigid bodies. Therefore, relaxation data can
be collectively taken as evidence that the full length protein
does not exhibit a rigid body hydrodynamics but experience
flexibility. Such flexibility must depend on the presence of a
flexible linker that permits sizable reciprocal mobility of the
two domains on a time scale that is faster than the reorientation
time of the whole molecule.
Figure 2. 900 MHz 15N-1H HSQC spectra of the uniformly 15N-labelled NNGH-inhibited, cadmium(II)-substituted Phe171Asp/Glu219Ala double mutant
of FL-MMP-12 (A), and superimposed spectra of FL-MMP-12 (black), CAT-MMP-12 (green), and HPX-MMP-12 (red) (B).
Table 1. 1H, 15N, and 13C Chemical Shifts for the Identified Linker Residues of FL-MMP-12
HN N CA HA CB other NOE
264 D 7.88 116.40 48.44 4.55 36.50 HB2 3.77, HB3 2.53
272 P 60.17 29.20 CG 24.29, CD 46.96
273 N 8.38 119.79 48.44 4.78 35.86 HB2 2.72, HB3 2.56 0.25
279 P 59.92 4.20 29.18 HB2 2.12, HB3 1.67, HG2 1.87, HG3 1.5, HD2 3.18, HD3 3.84
L1 8.28 120.71 53.34 4.17 29.97 QB 1.78, CG 38.97, QG 2.87
L2 8.17 109.42 57.03 4.83 39.62 HB2 3.05, HB3 2.60
L3 7.89 122.58 49.62 4.18
L4 8.16 121.91 53.24 4.19 30.91 0.28
L5 7.34 107.95 56.64 0.35
L6 8.37 123.69 51.65
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Indeed, three linker peaks (N273, L4, L5) display grossly
altered relaxation values, and particularly 15N-1H NOEs that
are sizably smaller than expected (0.25, 0.28, and 0.35
respectively; Table 1). This is another indication that the linker
is at least partially involved in some fast conformational
rearrangement, consistent with a sizable degree of reciprocal
mobility of the two domains. Incidentally, similar NOE values
were observed in the linker region of calmodulin, a two-domain
protein known to sample an extremely large conformational
space,43,45,50,88 and more recently in the two-domain xylanase
Cex.89 All R1 and R2 data on FL-MMP-12 and on its isolated
CAT and HPX domains, together with NOE data, are reported
in the Supporting Information (Table S7).
Residual Dipolar Couplings. Residual dipolar couplings
(RDC) in the presence of the external orienting device C12E5/
hexanol56 have been measured. They can be fitted very well to
the structures of the two isolated domains (Figure 4A,B)
separately, but with sensibly different orientation tensor values.
The data are, instead, in striking disagreement with the solid
state X-ray structure (Figure 4C). Figure 4D shows that the
agreement is modest also for any of the four rigid two-domain
structures that can be obtained by fitting both domains to a single
orientation tensor. None of these four structures bears a
resemblance with the X-ray structure in terms of relative domain
orientation (Figure S2, Supporting Information). These structures
are also different from any other X-ray structure of FL-MMPs.
On this basis, and on the basis of the relaxation data, these
solutions are discarded.
SAXS Experiments. The processed X-ray scattering pattern
from FL-MMP-12 presented in Figure 5 yields a molar mass
estimate of 40 ( 4 kDa, compatible with that calculated from
the sequence (42.5 kDa), indicating that the protein is mono-
meric in solution. The experimental radius of gyration Rg and
maximum size Dmax are 31 ( 1 Å and 110 ( 10 Å, respectively.
These values significantly exceed the parameters calculated from
the X-ray structure of FL-MMP-1 (Rg ) 25 Å, Dmax ) 85 Å),
while they are in better agreement with those computed from
the less compact X-ray structure of FL-MMP-12 determined in
the present study (Rg ) 29 Å, Dmax ) 95 Å). Moreover, the
scattering pattern calculated from the FL-MMP-1 model using
CRYSOL78 fails to fit the experimental data (discrepancy  )
5.8, curve 2 in Figure 5).
The scattering curve computed from the present FL-MMP-
12 structure displays a much better agreement to the experiment
( ) 2.5, curve 3 in Figure 5), but still displays some systematic
deviations. For flexible MMP-12, neither individual models, nor
averaging over the random pool allowed one to fit the SAXS
data. The representative ensembles selected to fit the data give
information about the preferable conformations of the protein.
Given the potential conformational flexibility of MMP-12 in
solution suggested by the NMR data, an alternative analysis
approach was applied, allowing for the coexistence of multiple
protein configurations. A large number of models was generated
(88) Bertini, I.; Del Bianco, C.; Gelis, I.; Katsaros, N.; Luchinat, C.; Parigi,
G.; Peana, M.; Provenzani, A.; Zoroddu, M. A. Proc. Natl. Acad.
Sci. U.S.A. 2004, 101, 6841–6846.
(89) Poon, D. K. Y.; Withers, S. G.; McIntosh, L. P. J. Biol. Chem. 2007,
282, 2091–2100.
Figure 3. Calculated (grey bars) and experimental (filled circles) backbone 15NH R1 (A, B) and R2 (C, D) values for the isolated CAT and HPX domains
(A, C) and for the full-length protein (B, D). Although the agreement between experimental and calculated R1 and R2 values for the isolated domains is
excellent, for the full-length protein the experimental R1 values are sizably larger (B) and the R2 values sizably smaller (D) than the ones calculated for the
rigid X-ray structure. Experimental NOE values for the full-length protein (E).
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obtained by the linker randomizations representing possible
conformations of MMP-12 in solution. None of these random
models yielded a computed scattering in agreement with the
experimental data. This was not unexpected, as SAXS “sees”
the conformational and orientational average over the large
(approx. 1016) ensemble of protein molecules in the illuminated
specimen volume. A simple average intensity of the generated
pool also did not agree with the experiment, suggesting a
nonrandom configuration of the linker in MMP-12. To assess
the preferable conformations in solution, the EOM method79
was used. Given a representative pool of (random) structures,
the method employs a genetic algorithm to select the ensembles
from this pool that best fit the experimental data, as explained
in materials and methods. Several EOM runs yielded reproduc-
ible ensembles neatly fitting the experimental data with dis-
crepancy  in the range 1.1-1.3, and a typical fit provided by
the ensemble selected by EOM is given in Figure 5, curve 4.
All the fits from different EOM runs are graphically indis-
tinguishable from curve 4 in Figure 5.
The Rg distributions of the particles in the initial pool and
in the selected ensembles are compared in the insert to Figure
5. The former distribution is rather broad, and covers the Rg
range from about 23 to 50 Å, corresponding to extremely
compact and completely extended domain configurations,
respectively. In contrast, the Rg distribution of the selected
ensembles displays a relatively sharp peak around Rg ) 28-29
Å, including about 55% of the particles in the selected
ensembles. Visual inspection of the models in the peak indicates,
not unexpectedly, that they have a shape similar to that of the
MMP-12 structure in the crystal (although with varying inter-
domain orientations). In contrast, not a single structure with Rg
< 27 Å was selected in multiple EOM reconstructions,
indicating that models similar to the crystal structure of FL-
MMP-1 were never present. These results indicate that the
present crystal structure of FL-MMP-12 may be significantly
present also in solution, but also that the protein experiences
noticeable conformational flexibility, as revealed by the presence
of a more or less uniform distribution of particles in the range
between Rg ) 30 and 50 Å and of a significant spike, which
was always observed for the most extended particles (Figure 5,
insert). We also tried to explore the possibility of a two-state
exchange situation allowing for only two conformations in the
mixture. The two-state fits were however always poorer than
those from twenty-state EOM populations. In particular, by
fixing the first state to be the crystal structure and allowing EOM
to select the second state, discrepancies not better than 1.5-1.6
could be obtained. These results suggest that MMP12 adopts a
manifold of conformations in solution, in full agreement with
NMR observations.
Concluding Remarks and Biological Implications
The present data demonstrate that full-length MMP-12 shows
relative mobility of its catalytic and hemopexin domains. The
observation of R1 and R2 values intermediate between those of
the isolated domains and those expected for any rigid structure
of the full-length protein is particularly striking in this respect.
Figure 4. Best fit vs experimental 900 MHz RDC values for the NNGH-inhibited, cadmium(II)-substituted Phe171Asp/Glu219Ala double mutant of FL-
MMP-12 in a binary mixture of C12E5 (penta-ethyleneglycol dodecyl ether) and neat n-hexanol. The separate fits for the CAT and the HPX domains and the
best fit orientation tensor values are shown in A and B respectively. The poor global fit assuming the rigid X-ray structure is shown in C, and that obtained
by best fitting the reciprocal orientation of the two domains to the RDC values is shown in D. In all panels, triangles refer to the CAT and filled circles refer
to the HPX domain.
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Indeed, even in the case of calmodulin, the two-domain protein
that constitutes a paradigmatic example of large interdomain
mobility,43,45,90,91 the R1 and R2 values are only modestly
different from what expected for a rigid structure.45,90 Appar-
ently, in the case of FL-MMP-12 the reorientation of the
backbone NH vectors with respect to the magnetic field occurs
on a time scale that is faster than the rotational time of the whole
molecule, whereas in calmodulin it is of the same order.45,90
Conversely, the amplitude of the motion is probably lower for
FL-MMP-12 than it is for calmodulin, as judged from the SAXS
data that suggest that the molecules spend about half of the
time in a conformation that is more or less as compact as the
solid state structure. A similar behavior is probably experienced
by the two-domain protein xylanase Cex, whose flexibility has
been recently demonstrated.89
The present data are a significant example of the synergy
between NMR and SAXS techniques.92–96 NMR provides
evidence of conformational freedom and of the time scale,
whereas SAXS provides insight into the types and variety of
the sampled conformations. About half of the conformations
that are likely to be experienced by FL-MMP-12 in solution
are as compact as the solid state structure but with different
relative orientations of the two domains, while another half a
re more extended, and some even highly extended. In this
respect the X-ray structure does not provide meaningful
information on the conformation of the protein in solution.
Relative mobility of the CAT and HPX domains has been
recently suggested for MMP-9, where the two domains are
separated by the OG domain.97 In the case of MMP-9 it has
been argued26 that the long and flexible OG domain may
mediate protein-substrate interactions. Independent domain
movements might even mediate enzyme translocation on a
collagen fibril.98,99 Another interesting possibility is that domain
flexibility can mediate the activation of the enzyme and the
cleavage of the pro-domain by promoting long-range confor-
mational transitions induced by the binding of the activator
proteins.100 It is possible that MMP-12 can be representative
of all other MMPs where the two domains are connected by a
short linker rather than by a long one (Figure 6). However, this
has to be demonstrated for those cases in which the contact
area between the CAT and HPX domains is much larger than
in the present case. Notably, the possibility of reorienting the
hemopexin with respect to the catalytic domain during catalysis
has been often invoked to rationalize the fact that, for collage-
nases (MMP-1, MMP8, and MMP-13), the catalytic domain
alone is not able to attack collagen, whereas the full-length
protein does.18,19
On the contrary, noncollagenase MMPs such as MMP-2 and
MMP-12 do not degrade the native triple helix collagen. The
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Zuiderweg, E. R. P. J. Am. Chem. Soc. 2005, 127, 828–829.
(91) Bertini, I.; Gupta, Y. K.; Luchinat, C.; Parigi, G.; Peana, M.; Sgheri,
L.; Yuan, J. J. Am. Chem. Soc. 2007, 129, 12786–12794.
(92) Mattinen, M. L.; Paakkonen, K.; Ikonen, T.; Craven, J.; Drakenberg,
T.; Serimaa, R.; Waltho, J.; Annila, A. Biophys. J. 2002, 83, 1177–
1183.
(93) Perry, A.; Tambyrajah, W.; Grossmann, J. G.; Lian, L. Y.; Scrutton,
N. S. Biochemistry 2004, 43, 3167–3182.
(94) Grishaev, A.; Wu, J.; Trewhella, J.; Bax, A. J. Am. Chem. Soc. 2005,
127, 16621–16628.
(95) Marino, M.; Zou, P. J.; Svergun, D.; Garcia, P.; Edlich, C.; Simon,
B.; Wilmanns, M.; Muhle-Gol, C.; Mayans, O. Structure 2006, 14,
1437–1447.
(96) Tsutakawa, S. E.; Hura, G. L.; Frankel, K. A.; Cooper, P. K.; Tainer,
J. A. J. Struct. Biol. 2007, 158, 214–223.
(97) Van den Steen, P. E.; Van Aelst, I.; Hvidberg, V.; Piccard, H.; Fiten,
P.; Jacobsen, C.; Moestrup, S. K.; Fry, S.; Royle, L.; Wormald, M. R.;
Wallis, R.; Rudd, P. M.; Dwek, R. A.; Opdenakker, G. J. Biol. Chem.
2006, 281, 18626–18637.
(98) Overall, C. M.; Butler, G. S. Structure 2007, 15, 1159–1161.
(99) Saffarian, S.; Collier, I. E.; Marmer, B. L.; Elson, E. L.; Goldberg,
G. Science 2004, 306, 108–111.
(100) Rosenblum, G.; Meroueh, S.; Toth, M.; Fisher, J. F.; Fridman, R.;
Mobashery, S.; Sagi, I. J. Am. Chem. Soc. 2007, 129, 13566–13574.
Figure 5. Experimental X-ray scattering from the NNGH-inhibited,
cadmium(II)-substituted Phe171Asp/Glu219Ala double mutant of FL-MMP-
12, and scattering from the models. (1) experimental data with error bars;
(2-3) computed scattering from the crystallographic models of FL-MMP-1
and FL-MMP-12, respectively; (4) a typical fit by the selected ensemble of
structures. The logarithm of the scattering intensity is plotted against the
momentum transfer. Insert: the frequency of the models with the given Rg
in the initial pool of structures with randomized interdomain linkers (blue
broken line) and in the selected ensembles (red solid line); the latter
distribution is obtained by the averaging of several EOM runs. Both Rg
distributions are normalized to the integral value of unity.
Figure 6. Linker lengths in matrix metalloproteinases. Arrows indicate
MMPs for which interdomain mobility has been demonstrated (26 and
present work).
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real function of these noncollagenase proteins is still unknown.
MMP-2 is able to degrade gelatin, a product of partial hydrolysis
of collagen, and MMP-12 elastin, but we do not know if these
are their real physiological roles. For MMP-12 it has been
reported that the catalytic domain alone is able to degrade elastin
even without the hemopexin domain. However, if during
evolution the hemopexin domain has been maintained in spite
of selective pressure, it is difficult to believe that it is useless.
In this respect, the present discovery of relative mobility of the
two domains in MMP-12 might be important for this still
unknown function.
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Abstract 
The design and synthesis of biotin chain-terminated inhibitor (BTI) showing high affinity 
for matrix metalloproteinases (MMPs) on one side and high affinity for avidin through 
the  biotinylated tag on the other, is reported. The affinity of the designed BTI towards 
five different MMPs has been evaluated and the formation of a highly stable ternary 
system Avidin-BTI-MMP clearly assessed. This system will permit the development of 
new approaches to detect, quantify and collect MMPs in biological samples, with 
potential applications in vivo. 
KEYWORDS:  MMPs, Probe, Biotin, NMR, X-ray 
 
Introduction 
 The design of molecular probes able to selectively bind biomolecular targets is 
gaining importance not only for their applications in molecular biology, but also for the 
development of new techniques for the early stage diagnosis and therapy of several 
pathologies.1 Rational drug design driven by structural data is currently applied to speed-
up the design of new candidate drugs in pharmaceutical research.2-5 The same approach is 
even more important to design molecular probes where, besides classical requirements, 
additive structural and functional features are required.  
Matrix metalloproteinases (MMPs), also known as matrixins, are proteinases that 
participate in extracellular matrix (ECM) degradation6 and in several extracellular 
processes.7-10 Under normal physiological conditions the activity of MMPs is strictly 
regulated by transcription/activation of zymogens precursors, interaction with specific 
ECM components and inhibition by endogenous inhibitors (TIMPs).11-14 An imbalance of 
these activities may results in diseases such as atherosclerosis, thrombosis or heart 
failure.15;16 As a matter of fact, expression and activation of MMPs are increased in these 
pathologies, as well as in almost all human cancers, compared to physiological 
conditions.17  
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MMPs have long been associated with cancer and metastasis. Indeed, ECMs 
degradation by MMPs does promote tumor invasiveness. Furthermore, it has been 
recently demonstrated that MMPs carry out functions other than promotion of invasion, 
and that they likely take part in the development of cancer even before invasion. 
Noteworthy, the degree of overexpression of MMP in cancer tissues is strictly associated 
with the level of tumor invasiveness and with its tendency to form metastasis. It is 
therefore apparent that the development of efficient molecular devices designed to reveal 
the overexpression of MMP may be a powerful tool for the early detection of tumors and 
the assessment of aggressiveness.18  
Studies focused on the detection of overexpression of MMPs have already been 
reported19 and probes to profile MMPs in tissues synthesized and tested.20;21 In particular, 
hydrolizable, near-infrared fluorescent molecules have been successfully tested in mice 
to detect fibrosarcoma.22 Unfortunately, this innovative technique suffers from the 
serious limitation represented by the limited penetration of light (a few millimetres); such 
a degree of penetration is only sufficient for the readout of superficial subcutaneous 
tumors (< 10 mm).  
An interesting approach to detect overexpression of MMP in atherosclerosis has 
also been published. Low molecular weight inhibitors, able to interact with the active site 
of MMPs involved in atherosclerotic plaque disruption, have been targeted with nuclear 
agents and tested in vivo.23-25 Although the results reported were extremely encouraging, 
the approach presented a scarce flexibility, due to experimental difficulties in preparing 
the targeted inhibitors and to limited availability of suitable nuclear agents. 
 A significant improvement in the development of MMPs-conjugated probes to 
detect pathological events may be the rational design of biotin-labeled inhibitors,26 
capable of binding to MMPs exclusively and with high affinity. These tagged molecules 
relay on the well known avidin-biotin molecular recognition system and could be used in 
conjunction to commercially available biotin-labelled probes (es. radionuclide chelates) 
to efficiently detect pathological tissues by imaging the local overexpression of MMPs. 
The use of such molecules is not limited to in vivo imaging but can be extended to in 
vitro applications such as MMPs purification by using avidin columns or devices. 
Capitalizing on our expertise on expression and structural characterization of 
MMPs27-29 and on the rational design and synthesis of MMP inhibitors,30-35 in the present 
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paper we report the design and synthesis of, carboxylic-based, biotinylated inhibitors able 
to show high affinity for several MMPs and at the same time able to strongly interact 
with avidin through the biotinylated tag. 
In clinical therapy, inhibitors’ selectivity for a specific MMP is dramatically 
important, so much so that the lack of selectivity is believed to have been the main reason 
for failures of clinical trials in the past. On the contrary, for the molecules here proposed, 
selectivity is not an issue. Indeed, ideal probes to detect overexpression of MMP, must 
not be selective inhibitors vs. a specific MMP but they should instead selectively 
recognize MMPs among other proteins. These new biotinylated molecules, designed to 
bind selectively to MMPs and to be recognized by avidin, might therefore be successfully 
used in the visualization of pathological tissues and to evaluate the aggressiveness of the 
pathology by monitoring radioactivity. Moreover, it might be possible to test in vivo the 
efficacy of clinical treatments against a specific disease by just monitoring the level of 
MMPs produced during the therapy. 
Results and Discussion 
Aryl-sulfonamide derivatives have been largely exploited to synthesize broad-
spectrum MMPs’ inhibitors. These scaffolds present different positions which can be 
easily functionalized by introducing new functional groups. This feature and their easy 
synthetic accessibility make sulfonamide derivatives suitable candidates to design biotin-
tagged probes for MMPs. As zinc binding groups (ZBG), the carboxylic acid was 
selected despite its relatively weak affinity for the metal ion.36;37 The choice of a 
carboxylic acid to replace the most commonly used hydroxammic acid warrants a higher 
stability of the inhibitor under physiological conditions, avoiding the formation of 
undesired and toxic degradation products. 
In all MMPs, the flexibility of the protein loops forming the active site makes 
these enzymes able to modify the shape of the catalytic pocket to accommodate ligands 
with different structures 38-41. In particular, analyzing the structures available on protein 
data bank, it is apparent that the volume of the S1’ cavity can be changed to host ligands 
bearing lipophilic groups of different size. However in MMP-1 and MMP-7 the S1’ cavity 
is so small that bulky groups generally misfits. Therefore, in order to probe all members 
of MMPs’ family, two scaffolds, bearing either a bulky biphenyl moiety or a smaller 
methoxyphenyl group, were considered as possible bases for the synthesis of BTIs.  
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Among all the scaffolds evaluated, molecules 1 and 2 (Figure 1) were selected for 
their low Ki values against five different MMPs (see Table 1). Noteworthy, the two 
scaffolds exhibit a sizable different selectivity and affinity for the MMPs chosen. In 
particular, inhibitor 1, due to the presence of a biphenyl moiety on the sulfonamide sulfur 
showed inhibition constants in the nanomolar range. Only for MMP-1 and MMP-7 the 
affinity was in the low-micromolar range due to the relatively small size of the S1’ 
pocket.42 On the contrary, 2 is a weaker MMP inhibitor with micromolar values of Ki for 
all the MMPs tested. 
Matrix metalloproteinase 12 (MMP-12) performs proteolysis of several ECM 
components including elastin, laminin and type IV collagen. The stability of the active 
MMP-12’s catalytic domain in the presence of weak inhibitors, the relatively large S1’ 
pocket, and the high yield of the 15N-enriched protein in minimal medium, make this 
enzyme an ideal model to evaluate BTI candidates. 
To explore the binding mode of the two scaffolds and to properly design the 
biotin-tag derivatives, the two inhibitors were soaked in crystals of MMP-12 and the 
structure of the complexes solved by X-ray crystallography. Analysis of the crystal 
structures (see Figure 2) revealed that the inhibitors share a similar binding mode, with 
the catalytic zinc ion coordinated by the oxygens of the free carboxylate, the sulfonyl 
oxygen H-bonded with the NH of the Ala 182, and the liphophilic groups nested inside 
the S1’ pocket. The structural analysis accounts for the larger affinity of 1 for MMP-12 
with respect to scaffold 2, as observed in the enzymatic assays. Indeed, in the MMP-12 - 
1 complex, larger hydrophobic interactions result from the larger surface-to-surface 
contact area due to the presence of the biphenyl moiety. More important for the biotin-tag 
inhibitors design was the solvent exposure of the sulfonamide nitrogen revealed by the 
crystal structures for both ligands. These structural data address the question related to 
the identification of the position where the tag can be inserted without spoiling the 
binding affinity.    
A further critical point in developing efficient biotinylated probes for in vivo and 
in vitro applications is represented by the choice of a suitable linker able to prevent any 
steric clashes between avidin and the target biomolecule. While a too short spacer may 
impair the ability of the probe to bind both MMP and avidin, the use of a too long spacer 
could affect the bioavailability, stability and solubility of the whole molecule. In 
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particular, a too long linker can increase the susceptibility of the probe to be split by 
enzymes such as the biotinidase that can degrade the molecule in vivo.43 Once more, the 
availability of the three-dimensional structure of both avidin (present in protein data 
bank, code: 2avi) and MMP-12’s catalytic domain provided the background information 
needed for a rational molecular design of the biotin-tagged inhibitors we conceived. 
A fourteen-membered spacer was designed to link the biotin residue to the 
carboxylic-methyl ester sulfonamide 3. 
The biotinylated inhibitor 4 was obtained by conjugating biotin aminoexylamide 
derivative 5 to the bromoexyl methylester 6, through a secondary amino group (Scheme 
1). Biotin was first reacted under known procedures43 with the N-Boc-1,6-diaminohexane 
7 to give the amido derivative 8 which, after removal of tert-butyloxy carbonyl protecting 
group, 11 was treated with the bromosulfonamide 6 in the presence of cesium hydroxide, 
in dimethylformamide as solvent, to give the enantiomerically pure ester 9 in 55% yield 
(see Supporting Information) (Scheme 2). Following the synthetic pathway reported for 4 
the biotin-tagged MMP-12’s inhibitor 10 was also prepared from 11 (Scheme 2) and 
bromosulfonamide 12 as diasteromerically pure compound (see Supporting Information) 
(Scheme 3).  
The affinity properties of the two BTI derivatives toward the selected MMPs were 
firstly evaluated by fluorimetric assay. While compound 4 had lower Ki values as 
compared to the corresponding precursor 1, BTI 10 exhibited comparable or weaker 
affinity with respect to its precursor 2. The micromolar Ki for all the tested MMPs 
unambiguously demonstrated that 10 could not have been used as a probe to detect these 
enzymes and it was not further investigated. Conversely, BTI 4 exhibited a high affinity 
for all the considered MMPs but one (MMP-1). The low affinity for MMP-1, already 
predicted during the design of the molecule, prevent the use of 4 to probe this enzyme. 
Several attempts aimed to obtain the X-ray structure of the biotin-tag inhibitors in 
complex with MMP-12, either by soaking or co-crystallization, failed, probably for steric 
reasons owing to the tag. Therefore, interaction of compound 1 and of its biotin-tag 
derivative 4 with the catalytic domain of MMP-12 was further investigated following the 
chemical shift perturbations on 15N-1H HSQC spectra using 15N labeled protein samples. 
The chemical shift is a sensitive indicator of protein-ligand interactions and can be use to 
identify the binding site when the resonance assignment is available.44 The complete 
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assignment of the catalytic domain of MMP-12 complexed with the weak inhibitor 
acetohydroxamic acid is available in our laboratory. Increasing amounts of 1 and 4 were 
added to 200 M solutions of the protein up to an equimolar concentration. Although 
several NH signals were shifted by adding the inhibitors, as many as 134 and 129 cross-
peaks belonging to protein adducts with 1 and 4, respectively, where easily re-assigned. 
The intensity of signals belonging to NH groups perturbed by the addition of the ligands 
decreased linearly, while new cross-peaks corresponding to the BTI-bound form of the 
protein appeared and gradually increased their intensity, in agreement with the effect 
produced by a slow-exchanging ligand.  
The binding mode of ligands 1 and 4, respectively, was analyzed and compared 
by reporting Garrett values [(NH)] on a surface representation of the MMP-12 
structure (Figure 3). As it is evident from Figure 3, for both inhibitors, the region with 
significant 15N-1H HSQC spectral perturbations involves the catalytic pocket. The 
analysis rule of Garrett values out relevant additive interactions of the biotinylated-tail 
present in BTI 4 with different protein regions, suggesting a different origin for the 
observed improved affinity. A hypothetical binding mode with the biotinylated-tail of 
BTI 4 fitting in the S1’ cavity can be completely excluded by the chemical shift 
perturbations on the 15N-1H HSQC spectra that are similar for 1 and 4 as well as by the 
Ki values of the BTI 10, which, although biotinylated, showed a low affinity for the 
enzyme. Conversely, the effects monitored on the aminoacids forming the catalytic 
pocket account for a better fit of 4 into the active site of the enzyme that stabilizes the 
protein-ligand adduct. 
Although a high affinity for the target protein is a basic requirement for the proposed 
bifunctional ligand to play its role, only the ability of the latter to bind MMP and avidin 
simultaneously could prove its real efficacy as effective BTI. Two different approaches 
based on NMR spectroscopy and on Surface Plasmon Resonance (SPR) respectively 
were followed to demonstrate the ternary Avidin-BTI-MMP interaction. Several NMR 
parameters are strongly influenced by the molecular weight and by the dynamical 
properties of the investigated macromolecules. Classical NMR experiments such as 15N-
1H HSQC usually performed to investigate biomolecules up to 30-40 kDa are inefficient 
for larger systems due to the fast transverse relaxation rate that broaden the signals 
beyond the detection threshold.45 Therefore, NH resonances can act as probes to 
investigate the formation of large protein-protein complexes.46 In the present case, the 
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evolution of the NH signals of the 15N MMP-12 catalytic domain complexed with the 
BTI 4 in 15N-1H HSQC spectra was exploited to monitor the interaction with non-labeled 
avidin, given that the binding of the biotin moiety to one of the four binding sites on the 
tetrameric avidin, should provide an 87 kDa. Since multiple binding for each avidin 
molecule may occur, even larger protein complexes are expected in solution. As shown in 
Figure 4 (panel D), the addition of an equimolar solution of the 65 kDa  avidin to a 
solution of the 15N labeled catalytic domain of MMP-12 complexed with the BTI 4 
caused the complete disappearance of all NH cross peaks without any precipitation of the 
sample.  
To exclude the presence of aspecific protein-protein interactions, avidin was 
added to a solution containing 200 µM of NNGH-inhibited-MMP-12 catalytic domain: in 
this case no changes were detected in the HSQC spectra map. Therefore, we can 
reasonably conclude that the strong protein-protein interaction, monitored by the 15N-1H 
HSQC experiments, is mediated by the BTI 4 which is able to bind MMP-12 and avidin 
and to prevent, at the same time, an extensive reciprocal reorientation of the complex 
subunits.  Although NMR data allowed us to ascertain that 4 does bind both avidin and 
MMP-12 side-by-side, the micromolar concentrations used for these experiments do not 
provide information on how this simultaneous interaction may affect the binding affinity 
of the inhibitor to MMP-12. Indeed, the maintenance of a nanomolar affinity for MMP-
12 of 4 when bound to avidin is a mandatory feature for a successful application of this 
BTI as probe  to detect MMP’s overexpression and activation, as well as to use the 
bifunctional linker for in vitro assays and in protein purification protocols.  
Reasonable steric effects related to the presence of the hemopexin domain need to 
be evaluated to demonstrate the real binding capability of the probe toward functionally 
active enzymes.47 In this respect, the availability of the active full length MMP-12 
allowed us to ascertain the efficiency of the biotinylated inhibitor to bind simultaneously 
avidin and the physiologically active enzyme. 
Surface Plasmon Resonance (SPR) is widely applied to investigate protein-
protein and protein-ligand interactions. Information on affinity constant, on binding 
kinetic as well as on binding enthalpy can be quickly obtained by using small amounts of 
protein samples. In particular, the sensitivity of the SPR technique permits to investigate 
high affinity interactions and to monitor the formation of ternary complexes. SPR 
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analysis were carried out using a ProteOn XPR36 parallel array biosensor equipped with 
avidin sensor chips (NLC). This chip has an avidin-coated surface that can be used to 
immobilize biotinylated molecules and macromolecules.48 In our study BTI 4 was 
immobilized on channels one to five of the chip by injecting PBS-T buffered solutions of 
the biotinylated molecule at different concentrations. The sixth channel was left as blank. 
The assay performed by injecting solutions of the full length MMP-12 on the chip 
channels and fitting the sensorgrams at four different concentrations. The measured KD 
(4.6 ± 0.3 nM) was in excellent agreement with the fluorimetric assay. 
Conclusion  
In summary, the present structure-based design led to the development of a potent 
biotin-probe to bind matrix metalloproteinases for possible application in vitro and in 
vivo. The structural requirements defined through the analysis of the X-ray structures 
allowed selecting the position on the scaffold where the linker could be introduced and 
the correct length of the biotinylated tag. As defined by NMR analysis, the origin of the 
larger affinity observed for BTI 4 is a better fit of the selected scaffold in catalytic pocket 
rather than additive interactions of the linker on the protein surface. The enzymatic assay 
demonstrated a nanomolar affinity of 4 not only for MMP-12 but also for MMP-7,-8,-13. 
Furthermore, the evolution of the 15N-1H HSQC spectra upon the addition of unlabelled 
avidin to solution of 15N  MMP-12 clearly showed that the fourteen-member spacer used 
to link the biotin unit to carboxylic arylsulfonamide inhibitor 1 and 2 to the biotin moiety 
ensures the simultaneous binding of the two proteins without permitting large 
interprotein mobility. SPR analyses clearly showed the ability of 4 to bind the functional 
active enzyme MMP-12 and avidin side-by-side. This simultaneous interaction did not 
affect negatively the nanomolar affinity of inhibitor 4 for MMP-12, given that the SPR 
data nicely reproduced the fluorimetric values. 
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Captions to the figures 
Figure 1. Structure of the selected scaffolds 1 and 2 
Figure 2. X-ray structure of the catalytic domain of MMP-12 complexed with 1 (A) and 
with 2 (B). Only the ligand-binding site is shown for clarity. 
Figure 3. Surface representation of the residues of the catalytic domain of MMP-12 
affected by chemical shift perturbation upon the addition of 1 (A) and of 4 (B). Areas of 
interaction with significant 15N-1H HSQC spectra perturbations are colored-coded 
according to the Garret values. Magenta  (NH)>0.1 ppm; Yellow  0.1>(NH)>0.05; 
Cyan 0.05>(NH)>0.03. 
Figure 4. 15N-1H HSQC spectrum of MMP-12 catalytic domain in absence (A) and in 
presence (B) of compound 1 (equimolar concentration). The two spectra are 
superimposed to highlight the cross-peak shifts (C). The ternary complex formation 
Avidin-BTI-MMP is seen in panel D where most of the cross peaks disappeared 
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Captions to the schemes 
 
Scheme 1.  Retrosynthesis of BTI 4 
Scheme 2. Synthesis of BTI 4 
Scheme 3. Retrosynthesis of BTI 10 
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Table 1. Inhibition constants ( Ki )of the considered compounds toward 
the considered MMPs. 
Compound MMP-1 MMP-7 MMP-8 MMP-12 MMP-13 
1 
2 
4 
10 
18  2 µM 
302  25 
µM 
25  3 µM 
295  40 
µM 
56   6 µM 
80  9 µM 
450  50 
nM 
73  7 µM 
31  4 nM 
4.6  5 µM 
4  0.5 nM 
8  1 µM 
25  2 nM 
1.4  0.2 µM 
5  0.6 nM 
1.6  0.2 µM 
108  12 
nM 
2.6  0.3 
µM 
0.7 0.2 nM
1.2  0.1 
µM 
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Structural and thermodynamic analysis of a selective ligand 
for matrix metalloelastase 
 
INTRODUCTION: 
The selectivity is a crucial property for a drug, since side effects often arise from the 
interaction with proteins different from the target. When the target is a member of a high 
homology protein family, the availability of highly selective inhibitors is even more 
important. The matrix metalloproteinases (MMPs) is a family of structurally related 
extracellular zinc endopeptidases responsible for the degradation of several extracellular 
matrix proteins (1). They play a critical role in both normal and pathological tissue 
remodeling processes (2). Their uncontrolled proteolytic activity has been associated with 
a variety of diseases, including cancer, arthritis, multiple sclerosis, and atherosclerosis (3). 
Therefore, there is substantial interest in developing MMP synthetic inhibitors for a 
variety of therapeutic indications. Results of the first clinical trials with broad spectrum 
MMP inhibitors in cancer therapy were disappointing, highlighting the need for better 
understanding of the exact role of each MMP during the different stages of tumor 
progression (4). Recent research in this field has focused on the development of inhibitors 
that fully differentiate one MMP from another. This is a particularly difficult task, since 
the topology and nature of the residues in the enzyme's active site are highly conserved 
among the different MMPs. Moreover, parts of the MMP catalytic domain, which play a 
critical role in enzyme specificity, seem to be highly flexible (5). This situation may 
explain why most previously reported MMP synthetic inhibitors preferentially inhibit 
some MMPs but are not exclusive inhibitors of a single MMP. Selective inhibitors for 
MMP-2, MMP-9 and MMP-12 have been reported recently (6). In particular, a phosphinic 
peptide derivative has been shown to be a highly selective inhibitor of MMP-12 (7). In 
such molecule an isoxazole ring placed in position P1', is used as a rigid scaffold to 
project in the right orientation a biphenyl moiety able to fit the S1' subsite of MMP-12. 
The two glutamates placed, respectively, in position P2' and P3' had been supposed to 
provide relevant interactions with aminoacids forming the catalytic pocket (8). The 
relevance of MMP-12 as potential drug target was the prompt to investigate the origin of 
the observed selectivity with the aim of designing new inhibitors. Site directed 
mutagenesis experiments have been carried out to establish the real role of Lys177 and 
Thr239 in ligand binding and selectivity. This biochemical information have been 
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integrated and supported by a structural analysis at the solid state and in solution. In 
particular, the three-dimensional structure of the protein-ligand complex has been solved 
by X-ray crystallography and the interaction in solution analyzed by NMR. Crystal 
structures obtained by soaking and co-crystallization have been compared in order to 
explore possible different binding modes. The chemical shift mapping has been exploited 
to reveal long distance perturbation effects of the ligand on the protein resonances and to 
evaluate the occurrence of small, but energetically relevant conformational 
rearrangements of protein regions (9). However, the structural data alone can not offer 
valuable insight into ligand selectivity since they do not provide information on the 
thermodynamics of the protein-ligand interaction. The analysis performed by Isothermal 
titration calorimetry (ITC) has revealed the thermodynamic driving force responsible for 
the picomolar affinity of the considered inhibitor allowing to new structure/energy 
correlations and toward new hypothesis on the origin of the observed selectivity. 
 
MATERIALS AND METHODS: 
Synthesis, characterization and inhibitory assays of the phosphinic inhibitor 1 toward 
MMP-12 have been already described (10).  
Expression and purification of human MMP12 catalytic domain: The cDNA, encoding 
the fragment Gly106-Gly263 of the macrophage metalloelastase, was cloned into the 
pET21 vector (Novagen) using NdeI and BamHI as restriction enzymes and then 
transfected into E. coli strain BL21 Codon Plus cells. Uniform 15N labelled protein was 
expressed by induction with 0.5 mM of IPTG at 37 C° for 4 h in M9 minimal media 
containing 15 mM of (15NH4)2SO4 and 13C enriched glucose (Cambridge Isotope 
Laboratories).  The inclusion bodies, containing the protein, were solubilized in a 
buffered solution with 20 mM Tris-HCl and 8 M urea at pH 8. The protein was then 
purified with a size exclusion chromatography (Pharmacia HiLoad Superdex 75 16/60) in 
6 M urea and 50 mM sodium acetate. A second step of purification was performed on 
cation exchange column Mono-S (Pharmacia) using a linear gradient of NaCl up to 0.5 
M. 
The protein was refolded by using a multi-step dialysis against solution containing 50 
mM Tris-HCl (pH=7.2), 10 mM CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl and decreasing 
concentration of urea (from 4 M up to 2 M). The last two dialysis were performed against 
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solution containing 20 mM Tris-HCl (pH=7.2), 5 mM CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl 
and 200 mM of hydroxamic acid (AHA). 
Fluorimetric assays. The inhibition constants for the compounds here investigated were 
determined evaluating their ability to prevent the hydrolysis of the fluorescent-quenched 
peptide substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (Biomol Inc.). All 
measurements were performed in 50 mM HEPES buffer, with 10 mM CaCl2, 0.05% Brij-
35, 0.1 mM ZnCl2 (pH 7.0), using 1 nM of enzyme and 1 μM of peptide at 298 K.  
NMR measurements and assignment of the protein backbone 
The experiments for the assignment of the protein backbone where performed on protein 
sample at a concentration of 0.7 mM (pH 7.2).  
All NMR experiments were performed at 298 K and acquired on Bruker AVANCE 900, 
equipped with triple resonance CRYO-probes.  
All spectra were processed with the Bruker TOPSPIN software packages and analyzed by 
the program CARA (Computer Aided Resonance Assignment, ETH Zürich) (11).  
The backbone resonance assignment was obtained by the analysis of HNCA, HNCO, 
HNCACB and CBCA(CO)NH spectra performed at 900 MHz. 
Crystallization, Data Collection and Resolution of the Crystal Structures: Crystals of 
human MMP12, already containing AHA from the refolding process, grew at 293 K from 
a 0.1 M Tris-HCl, 30% PEG 8000, 200 mM AHA, 1.0 M LiCl2 solution at pH 8.0 using 
the vapor diffusion technique. The final protein concentration was about 10 mg/ml. 
The complexes were obtained through soaking MMP12-AHA crystals with a solution 
containing the inhibitor itself in the presence of LiCl2.  
For the co-crystallized MMP12–Phosphinic adduct, 3 mM of NNGH was added to 
protein solution before mixing with a reservoir buffer containing 0.1 M Tris_HCl, 20% 
PEG 6000, 200 mM AHA, and 1.0 M LiCl2 at pH 8.0. 
The data were measured in-house, using a PX-Ultra copper sealed tube source (Oxford 
Diffraction). 
All the datasets were collected at 100 K and the crystals used for data collection were 
cryo-cooled without any cryo-protectant treatment. The crystals of all complexes had a 
mosaicity ranging from 0.3° to 0.8° and diffracted to a maximum resolution of 1.1 Å.  
All the soaked adduct crystallize in the C2 space group with one molecule in the 
asymmetric unit while co-crystallized complex of inhibitor crystallizes in P21212 space 
group with one molecule in the asymmetric unit.  
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The data were processed in all cases using the program MOSFLM (12) and scaled using 
the program SCALA (13) with the TAILS and SECONDARY corrections on (the latter 
restrained with a TIE SURFACE command) to achieve an empirical absorption 
correction. 
The structure of adduct with inhibitor was previously solved (14) using the molecular 
replacement technique; the model used was that of a molecule of human MMP12 (1OS9) 
while the structure of all other adducts were solved using the MMP12-AHA adduct 
(1Y93) as the model from where the inhibitor, all the water molecules and ions were 
omitted. The correct orientation and translation of the molecule within the 
crystallographic unit cell was determined with standard Patterson search techniques (15, 16) 
as implemented in the program MOLREP (17, 18). The refinement was carried out using 
REFMAC5 (19) and for the atomic resolution datasets anisotropic B-factors were also 
refined. In between the refinement cycles the models were subjected to manual rebuilding 
by using XtalView (20). The same program has been used to model all inhibitors. Water 
molecules have been added by using the standard procedures within the ARP/wARP suite 
(21) and for the atomic resolution datasets hydrogens were added at the riding positions 
and refined. 
The stereochemical quality of the refined models was assessed using the program 
Procheck (22). The Ramachandran plot for all structures is of very good quality. 
The coordinates for all adducts are under deposition at the ProteinDataBank. 
 
Calorimetry: The thermodynamic characterization of the interaction between the 
phosphinic inhibitor and the catalytic domain of MMP-12 has been carried out by 
performing ITC experiments at 298 K with a VP-ITC instrument (MicroCal, Inc., 
Northampton, MA). After an initial injection of 1 μL of 136 μM inhibitor, subsequent 
aliquots of 10 μL were stepwise injected into the sample cell containing a 12 μM solution 
of MMP12 catalytic domain (G106-G263), until complete saturation. All experiments 
were performed in 20 mM Tris (pH 7.2), 5 mM CaCl2, 0.1 mM ZnCl2, 0.1 M NaCl.  
Heats of dilution were measured by injecting the ligand into buffer and then subtracting 
the obtained values from the heats of binding. The thermodynamic parameters and KA 
values were calculated fitting data to a single binding site model with ORIGIN 7.0 
software (Microcal, Inc.) (23). 
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RESULTS AND DISCUSSION: 
Site-directed mutagenesis studies: Several hypothesis on the structural determinants 
responsible for the tight binding and the high selectivity of phosphinic peptide inhibitor 
toward MMP-12, were based on a molecular model, generated starting from the x-ray 
data on a structurally related phosphinic inhibitor bound to the catalytic domain of MMP-
11. The model revealed a close proximity of Glu in position P2′ and Glu in P3′ to Thr239 
and to Lys177 respectively, suggesting a role of these two residues in ligand binding and 
in selectivity. To prove or disprove this hypothesis, a mutant of the catalytic domain of 
MMP-12, where Thr239 and to Lys177 were replaced by two glycine, has been expressed 
and the affinity for the phosphinic inhibitor determined by a fluorimetric assay. The Ki 
value was still in the picomolar range and in good agreement with that obtained for the 
wild-type protein. The retained affinity of the inhibitor for the mutant demonstrates that 
the interactions suggested by the model are too weak or even completely absent. The 
failure of the model in predicting the protein-ligand interactions was the prompt for a 
structural characterization of the complex.  
 
Crystal structures In the crystal structures of the soaked and co-crystallized complex the 
inhibitor shows a similar but not identical binding pose.  
Given the active site topology of MMPs, most inhibitors share similar features, i.e., the 
ability to bind to the metal ion, to the hydrophobic pocket termed S1′, and to the substrate 
binding groove. The phosphinic moiety is targeted to bind the catalytic zinc ion through 
one of the two oxygen atoms at a distance of 1.85 Ǻ; the coordination environment for Zn 
is completed by His218, His222 and His228. The aromatic ring directly bound to the 
phosphinic group is involved in a stacking interaction with the ring of His222. The 
bromine atom bound to the latter ring is at 2.7 Ǻ distance from the oxygen atom of 
Ala184 backbone. The bulky polycyclic aromatic part is targeted to deeply enter into 
hydrophobic S1′ pocket, to remove several waters molecules filling the cavity and to 
establish hydrophobic interactions. 
The peptidic part shows significant H-bond interactions with the residues flanking the 
binding groove: four such interactions are present with the backbone atoms of Gly179, 
Leu181, Pro238 and Tyr240 with distances ranging from 2.5 Ǻ to 3.3 Ǻ.  
A close up of the arrangement of the ligand in the active site of MMP12 is shown in 
Figure 1. As expected, the inhibitor share the same binding mode of other inhibitors 
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known in the literature and all relevant interactions (with the S1′ pocket, the metal, and 
the substrate binding groove) are in place. The comparison of the crystal structure of 
MMP-12-phosphinic complex with the free form of the protein has provided an insight 
into the effect of ligand binding on protein flexibility.  The least-squares superposition 
between Free-MMP12 (2OXU) and MMP12–Phosphinic yields a global BB RMSD of 
0.47 Å with only two narrow regions in which the deviation is significantly high: region 
154–155 where it goes up to 1.7 Å, and region 230–233 where it goes up to 1.4 Å (Fig. 
1B). Also the comparison of MMP12–Phosphinic with the NNGH inhibited structure 
(PDB code 1RMZ) has provided similar results, with a global BB RMSD of 0.41 Å and 
with major deviations localized in the same regions. Interesting, it is also the comparison 
between the soaked and co-crystallized structure of the MMP-12-Phosphinic inhibitor. 
For these two structure, the least-squares superposition yields a global BB RMSD of 0.53 
Å, with large deviation again restricted to the same backbone segments. Collectively, 
these data provide an assessment of the conformational heterogeneity, previously 
reported for the same regions of the catalytic domain of MMPs, but more important, 
suggest that the mobility in these protein areas in not reduced by the interaction with the 
phosphinic inhibitor. 
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Since chemical shifts are very sensitive to small changes in intermolecular interactions, 
the analysis of the Garret values [Δδ(NH)] provides a detailed map of the protein residues 
affected by the interaction upon the addition of the phosphinic inhibitor to the protein 
containing the weak inhibitor AHA.  
 
As it is evident from Figure 2 (A) and (B), the aminoacids with significant 15N-1H HSQC 
spectral perturbations involves not only those forming the catalytic pocket but several in 
regions far from the catalytic site. The comparison with the Garret values obtained for the 
MMP-12 inhibited by NNGH, show as the both NNGH and the Phosphinic inhibitors 
affect the same protein regions. At the same time, the inspection of the histograms 
highlights a larger effect of the phosphinic inhibitor on the protein resonances. 
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The residues whose resonances are most affected upon binding are color-coded in Figure 
3, where the solvent-accessible surface area of the protein is represented. The colors 
range from black ((ave > 0.5 ppm), to dark red (0.5 > (ave > 0.2 ppm), to orange (0.2 > 
(ave > 0.1 ppm), to yellow (0.1 > (ave > 0.05 ppm) up to white ((ave  0.05 ppm) 
 
 
 
Thermodynamics of ligand binding:  
The free energy of the protein-ligand interaction is composed by enthalpic and entropic 
terms (24). However, the analysis of such interactions on the crystal structures may 
account only for the enthalpic contribution. Reliable information on both, enthalpic and 
entropic contribution to the ligand binding can be obtained by performing Isothermal 
titration calorimetry (ITC) experiments (25, 26).  
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The analysis provided an accurate measurement of the ΔH0 (+11.8 kcal/mol) associated 
with the binding of the phosphinic inhibitor to the protein. The endothermic peaks 
(Figure 4) associated with the addition of the phosphinic inhibitor show that, in this 
buffer, the interaction is strongly entropically driven. Indeed, the unfavorable enthalpy 
term must be offset by a large entropic contribution, given that the KD is in the picomolar 
range (if the 0.19 nM from Dive et al., (27) is taken, a -TΔS0 = -25 kcal/mol is obtained). 
This extremely high affinity makes ITC data unsuitable to estimate the binding constant 
of the inhibitor for MMP-12. Therefore, estimates of -TΔS0 values were obtained by 
using the corrected ΔH0 values from calorimetry and the ΔG0 values from fluorimetry 
measurements.  
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Figure 4. ITC data on the binding of the phosphinic inhibitor to MMP-12. [note that the free energy and 
therefore the entropy calculated from the data are meaningless, given the subnanomolar dissociation 
constant measured from fluorimetry]. 
 
The here presented data are consistent with a model where, upon the binding, the polar 
groups of the protein and of the ligand undergoes to desolvation without establishing new 
strong interactions. At the same time, the release of water molecules provides the large 
and positive entropy contribution. The extent of the entropic contribution suggests also a 
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relatively small loss of conformational degrees of freedom of both the drug molecule and 
the protein molecule upon the binding (28, 29, 30). This hypothesis is in agreement with the 
analysis of the crystal structures where the conformational heterogeneity in well defined 
protein regions is preserved upon the binding with phosphinic inhibitor. 
 
CONCLUSION: 
The interaction of the highly selective picomolar inhibitor of MMP-12 with its protein 
target has been investigated in solution and in solid state. The ligand establishes several 
interactions with the aminoacids forming the active site and with the catalytic zinc ion.  
The long three-cyclic moiety fits the S1’ pocket so removing the several waters 
molecules buried inside the cavity. The role of the two aminoacids supposed to be 
responsible for the observed selectivity has been demonstrated to be uninfluential in 
ligand binding and in selectivity. The thermodynamic investigation performed by ITC 
shows that the interaction is entropically driven. An extensive desolvation and a small 
loss of conformational entropy of both the protein and the ligand are probably responsible 
for the tight binding. The ability of the ligand to perform an extensive binding without 
drastically reducing the protein flexibility could be the origin of the selectivity for MMP-
12. 
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General Discussion: 
The final aim of PhD thesis work can be described even with the sentence 
“Understanding the molecular mechanistic of the Inhibitors/Substrates-MMP12 
interaction and to improve the drug designing strategies for this protease”. 
 
Cat, Hpx and Full-length MMP12 (wild type and various mutants) were expressed during 
the course of PhD. The protocols and strategies developed during the project resulted in 
better yield of purified stable samples of protein. These samples allowed us to deeply 
investigate the molecular mechanism of MMP12. Catalytic activation as well the 
interaction. If it is true that we focused our study on MMP12, then our findings might be 
applicable to whole MMP family or any structurally characterized target. We give an 
important contribution to the understanding of the mechanicistic features of MMP12 as 
well as MMPs. The present studies are a significant example of the synergy between 
various biophysical and biochemical techniques. 
 
The relatively mobility of Cat and Hpx like domains has been verified which led to the 
possibility that domain flexibility can mediate the activation of the enzyme. These results 
can be representative for other members of MMP family having the short linker region 
between the two domains and help to understand the role of mobility on substrate 
recognition and on catalytic mechanism. Moreover the preliminary results of the 
interaction studies of MMP12 full length as well Cat and Hpx domain individually with 
physiological substrate elastin and its subunits are exciting and fruitful in understanding 
the long debated role of Hpx domain in binding and catalysis of substrate for this 
enzyme. This provides us the possibility to deeply investigate the mechanism of substrate 
recognition by MMP12 and in general similar class of MMPs. 
 
The knowledge of the catalytic mechanism of MMPs is a key-tool for understand how to 
design more selective inhibitor. The presented data by combining the structural 
information with thermodynamic studies provided hints for the possibility of designing 
selective inhibitor with increased affinity for MMP12. This structural determinant studies 
helped to have a better looks insight of the interaction and thus inhibition. Further the 
structure based drug designing led to development of biotinylated-probe for profiling 
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MMP12 in particular and some other member of the MMP family. Such activity based 
bifunctional probes could be of high importance and efficacy in vivo and in vitro. 
 
Future Perspective: 
The initial results for interaction studies of MMP12 and Elastin and its two components 
are interesting and exciting. The future course of work is to understand the molecular 
mechanistic and to address the potential role of Hpx role in substrate recognition by 
MMP12 and the structural determinants responsible for the interactions. The long term 
perspective is to investigate the mechanism of activation of full length MMP12 (Pro-Cat-
Hpx) and to verify the inter domain mobility for other members of MMP family. 
Further, activity based probes for profiling of various MMPs in different pathological 
conditions and designing of selective inhibitors for metalloelastase as well as other 
members of family is one of the important parts of future work. 
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